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Abstract
The ATP-binding cassette (ABC) transporters play an important role as a barrier to protect cells from the
accumulation of toxic xenobiotics and metabolites due to their ability to translocate a wide array of
compounds across lipid bilayers. However, many ABC transporters, especially the ones localized in the
intracellular organelles, are involved in critical biological processes such as antigen presentation. The
core unit of ABC transporters contains two functional domains: the membrane spanning domain (MSD)
and the nucleotide binding domain. The full transporters contain two of these units in tandem in a single
polypeptide, whereas the half transporters only contain one and must homo- or hetero-dimerize in order to
exert their functions. A half transporter ABCB6 has been shown to localize in mitochondria and suggested
to play a role in iron homeostasis; however, its function remained elusive. Therefore, we aimed to
characterize several aspects of ABCB6: identification of substrates, physiological role, transport
mechanism and intracellular trafficking. In this study, we show that ABCB6 is a homodimeric
mitochondrial outer membrane protein. Furthermore, we identified ABCB6 as a porphyrin transporter that
facilitates heme biosynthesis, in which the intermediates must be shuttled between mitochondria and the
cytosol. Translocation of substrates by ABC transporters occurs in an ATP-dependent manner, although
the role of ATP binding and hydrolysis in the transport process remains controversial. Taking advantage
of its ability to bind hemin conjugated to agarose beads, we demonstrate that the ATP binding at the NBD
is sufficient to induce a conformational change to a low affinity state in ABCB6. In an attempt to
understand how ABCB6 trafficks intracellularly, we identified a post-translational modification that
indicates ER to Golgi trafficking during its maturation. Moreover, we identified a novel N-terminal disulfide
bond that plays an important role in the ER exit of ABCB6. This disulfide bond motif is found in other ABC
family members and the loss of the conserved cysteine residue in ABCC8/SUR1 is the genetic basis for
hyperinsulinemic hypoglycemia. Because ER redox status appears to play an important role in the
trafficking of these proteins, expression patterns of ABC transporters may be altered in
pathophysiological conditions such as diabetes where microsomal redox status is shifted.
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ABSTRACT
The ATP-binding cassette (ABC) transporters play an important role as a barrier
to protect cells from the accumulation of toxic xenobiotics and metabolites due to their
ability to translocate a wide array of compounds across lipid bilayers. However, many
ABC transporters, especially the ones localized in the intracellular organelles, are
involved in critical biological processes such as antigen presentation. The core unit of
ABC transporters contains two functional domains: the membrane spanning domain
(MSD) and the nucleotide binding domain. The full transporters contain two of these
units in tandem in a single polypeptide, whereas the half transporters only contain one
and must homo- or hetero-dimerize in order to exert their functions. A half transporter
ABCB6 has been shown to localize in mitochondria and suggested to play a role in iron
homeostasis; however, its function remained elusive. Therefore, we aimed to characterize
several aspects of ABCB6: identification of substrates, physiological role, transport
mechanism and intracellular trafficking. In this study, we show that ABCB6 is a
homodimeric mitochondrial outer membrane protein. Furthermore, we identified ABCB6
as a porphyrin transporter that facilitates heme biosynthesis, in which the intermediates
must be shuttled between mitochondria and the cytosol. Translocation of substrates by
ABC transporters occurs in an ATP-dependent manner, although the role of ATP binding
and hydrolysis in the transport process remains controversial. Taking advantage of its
ability to bind hemin conjugated to agarose beads, we demonstrate that the ATP binding
at the NBD is sufficient to induce a conformational change to a low affinity state in
ABCB6. In an attempt to understand how ABCB6 trafficks intracellularly, we identified a
post-translational modification that indicates ER to Golgi trafficking during its
maturation. Moreover, we identified a novel N-terminal disulfide bond that plays an
important role in the ER exit of ABCB6. This disulfide bond motif is found in other ABC
family members and the loss of the conserved cysteine residue in ABCC8/SUR1 is the
genetic basis for hyperinsulinemic hypoglycemia. Because ER redox status appears to
play an important role in the trafficking of these proteins, expression patterns of ABC
transporters may be altered in pathophysiological conditions such as diabetes where
microsomal redox status is shifted.
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CHAPTER 1. INTRODUCTION
1.1. Historic Overview: Discovery of P-glycoprotein and ABC Protein Superfamily
... in resistant cells there is an outward flow of daunomycin which is against an
electrochemical gradient, carrier mediated, and dependent on the energy metabolism.
Dano, K., Active outward transport of daunomycin in resistant Ehrlich ascites
tumor cell, p. 480 [1].
The adenosine triphosphate (ATP)-binding cassette (ABC) transporters in the
ABC protein superfamily translocate various molecules across lipid bilayers in an
energy-dependent manner. Because of their wide array of substrates, genetic variations in
ABC transporters are now known to be involved in the pathophysiology of numerous
human disorders (Table 1.1.)[2]. ABC proteins comprise one of the largest protein
superfamilies with 48 members identified to date in humans. The first mammalian ABC
protein was discovered in 1976 as a 170-kDa membrane glycoprotein that was
overexpressed in colchicine resistant cell lines [3]. These cells were cross-resistant to
different classes of drugs, and it was speculated that this protein altered drug permeability
at the membrane resulting in a lower accumulation of drugs in resistant cells. Thus, this
protein was named P glycoprotein (P-gp) for glycoprotein that reduces drug permeability.
Many had suspected early on that multidrug resistance (MDR) would be a major obstacle
in treating complex diseases such as cancer. By 1960’s, several groups found a
correlation between drug accumulation and drug response [4-6]; however, the uptake
(influx) and efflux of drugs were not discriminated, and they simply speculated that the
rate of uptake was altered in the drug resistant cells. In 1973, Dano provided definitive
evidence of active efflux of daunomycin by measuring the steady state intracellular and
extracellular drug accumulation in parental and daunomycin resistant cell lines [1]. Also,
a metabolic inhibitor, β-deoxyglucose, was shown to inhibit the efflux of daunomycin.
From these experiments, Dano concluded that “in resistant cells there is an outward flow
of daunomycin which is against an electrochemical gradient, carrier mediated, and
dependent on the energy metabolism” [1], which accurately predicted the function of yet
to be identified ABC transporters.
While Ling and his colleagues observed P-gp gene (~4.7 kilobases (kb))
amplification in different MDR mammalian cell lines and were determined to identify the
role of P-gp in MDR [7], Roninson and colleagues identified and isolated DNA
sequences that were commonly amplified in several MDR cell lines [8]. Of the many
amplified DNA sequences observed, one such region, mdr, was isolated, which was
found to contain a gene that transcribed ~5 kb mRNA [9]. Gros and the colleagues then
went on to show that the ectopic expression of mouse mdr1 cDNA conferred MDR in
drug-sensitive Chinese Hamster cells [10]. However, the relationship between P-gp and
mdr was not clear at this point. Using P-gp specific antibody and cross-hybridization of
P-gp probe and mdr1 cDNA, Ueda et al. finally showed that the mdr1 gene product is Pgp [11]. It became clear from different approaches to identify mechanisms of MDR
phenotypes that P-gp, the product of mdr1, was one of the key players in MDR.
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Table 1.1. Diseases and phenotypes caused by mutations or a lack of ABC genes.
Gene

Mendelian disorder/phenotype

Reference

ABCA1
ABCA3
ABCA4
ABCA12
ABCB1
ABCB2
ABCB3
ABCB4
ABCB7
ABCB11
ABCC2
ABCC6
ABCC7
ABCC8
ABCC9
ABCC11
ABCD1
ABCG2
ABCG5
ABCG8

Tangier disease, FHDLD
Lung Surfactant deficiency
Stargards/FFM, RP, CRD
Lamellar and harlequin ichthyosis
Ivermectin sensitivity (in collie dogs)
Immune deficiency
Immune deficiency
PFIC-3
XLSA/A
PFIC-2
Dubin-Johnson syndrome
Pseudoxanthoma elasticum
Cystic fibrosis
FPHHI
DCVT
Dry ear wax
ALD
Porphyria (observed in mouse)
Sitosterolemia
Sitosterolemia

[12-16]
[17]
[18, 19]
[20]
[21, 22]
[23, 24]
[23, 24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[36]

Abbreviations used are ALD, adrenoleukodystrophy; CRD, cone-rod dystrophy; DCVT,
dilated cardiomyopathy with ventricular tachycardia; FFM, fundus flavimaculatus;
FHDLD, familial hypoapoproteinemia; FPHHI, familial persistent hyperinsulinemic
hypoglycemia of infancy; PFIC, progressive familial intrahepatic cholestasis; RP, retinitis
pigmentosum 19; XLSA/A X-linked sideroblastic anemia and ataxia.
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The clue to the function of P-gp/MDR came from findings in bacterial
periplasmic binding protein-dependent transport systems (early name for bacterial ABC).
A conserved nucleotide-binding fold [37], containing Walker A and B, was found in
hisP/malK/oppD, components of different transport systems, and oppD indeed bound to
an ATP analog [38]. These findings led to a model that these transport systems were
energy-dependent and ATP hydrolysis at hisP/malK/oppD were responsible for a
conformational change to transmit the information to the substrate binding component
[38]. By using the deduced amino acid sequence of P-gp/mdr, it was shown that P-gp/mdr
shared a high sequence homology with hisP/malK/oppD [39, 40] and hlyB [41] at the
nucleotide-binding fold. Combined with the prediction from hydropathy plots, the
proposed model of P-gp/MDR comprised of two highly conserved units, six putative
membrane-spanning regions followed by a cytoplasmic nucleotide-binding fold, in
tandem [39, 40]. From the sequence homology with the bacterial transport systems, it was
proposed that P-gp/MDR is an energy-dependent transporter that is involved in the efflux
of drugs to reduce the drug accumulation in MDR cells [39-41]. By this time, it was
realized that ABC proteins comprised a large protein superfamily [42] conserved from
bacteria to mammals [43].
Forty-eight human ABC genes are classified into seven subfamilies (A to G)
based on the gene structure, amino acid alignment especially of nucleotide binding
domains (NBD), and phylogenetic analysis and are named according to Human Genome
Organization (HUGO) guidelines established in 1999 (P-gp/MDR1 is ABCB1 under the
new nomenclature, http://www.genenames.org/genefamily/abc.php)[44]. ABC gene
homologs found in other species, e.g., mouse, drosophila, are also classified into similar
subfamilies. ABC proteins are characterized by the presence of Walker A and B motifs,
which can be found in other ATP binding proteins, and an additional element, the
signature motif, in NBD. Except for ABCE and F subfamilies, all ABC proteins also
contain one or two sets of membrane spanning domains (MSD) consisting of six to
eleven α-helices. These MSD-containing ABC proteins will be referred to as ABC
transporters hereafter although some of them, namely ABCC7, ABCC8, and ABCC9, are
not typical transporters. ABC transporters can further be classified into two types by the
number of functional units they contain. Functional transporters consist of two sets of
MSDs and NBDs (Fig. 1.1.); full transporters contain two MSDs and NBDs in a single
polypeptide, whereas half transporters contain only one MSD and NBD, thus are required
to either homo- or heterodimerize in order to exert their functions. Full transporters are
found in ABCA, ABCB, and ABCC subfamilies and half transporters are grouped into
ABCB, ABCD and ABCG subfamilies.
1.2. ABC Transporters
Although ABC transporters were initially identified from MDR cells and were
implicated in MDR phenotypes, subsequent studies have shown that ABC transporters
have more fundamental roles: moving molecules, whether xenotoxins or biological
molecules, across the cell membranes in an energy-dependent and unidirectional manner.
While most of the prokaryotic ABC proteins pump in compounds, mainly nutrients, from
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Figure 1.1. Schematic representations of ABC transporters.
A. Full transporters contain two sets of MSDs and NBDs in tandem. In addition, long
MRPs contain an extra MSD, MSD0. Domain structure of NBD is shown on the upper
panel. B. Half transporters contain one set of MSD and NBD. ABCG proteins have a
reversed orientation of MSD and NBD. Some ABCB half transporters contain an
additional 3 – 5 TM helices. MSD, Membrane spanning domain; NBD, nucleotide
binding domain; TM, transmembrane helices.
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Figure 1.1. (continued).

6

the extracellular milieu into the cells, eukaryotic ABC transporters typically move
molecules from the cytoplasm to the extracellular compartment or into cellular
organelles. Functions of some ABC transporters were identified through linkage analysis
with known human disorders, tissue distribution patterns, and/or animal models.
1.2.1. ABC Transporters and MDR Phenotypes
Multidrug resistance frequently develops in patients undergoing chemotherapy
and is one of the major reasons for the relapses observed. Mechanisms of MDR have
been extensively studied for numerous agents and can be classified into either one or a
combination of the following three patterns: i) decrease in the levels of uptake carriers for
drugs that do not cross the membranes by passive diffusion, ii) mutations in the target
molecules or target pathways so that the drugs are no longer effective, and iii) increase in
levels of the transporters that efflux mainly hydrophobic drugs. Because many ABC
transporters are able to efflux structurally different classes of drugs, changes in their
expression levels can explain MDR phenotypes in many cases. Indeed, when MDR
phenotypes developed in “spontaneous” mammary tumors from Brca1-/-/p53-/- conditional
mice in response to doxorubicin, Mdr1a and Mdr1b (mouse P-gp/MDR1) were
consistantly upregulated in many of the tumors investigated [45]. The tumors also
became cross-resistant to docetaxel, an excellent P-gp/MDR1 substrate, and became
sensitive to doxorubicin when treated with a P-gp inhibitor suggesting that the
upregulation of Mdr1 genes were responsible for the MDR phenotype [45].
Prior to 1991, P-gp was believed to be the only drug efflux transporter. However,
“atypical” MDR phenotypes paved the way for identification of new ABC transporters
that ply a role in MDR. For example, by taking an advantage of a doxorubicin-selected
small cell lung cancer cell line, H69AR, with no P-gp overexpression, Cole et al.,
identified an ABC transporter, MRP1 (ABCC1) termed for multidrug resistanceassociated protein 1 [46]. In a concerted approach to identify P-gp independent
resistance, Ross and colleagues utilized a cell line that was selected for doxorubicin
resistance, but treated with the P-gp inhibitor, verapamil. From MCF7/AdrVp cell line,
the third major drug transporter, breast cancer resistance protein (BCRP, also known as
ABCG2), was identified [47]. When BCRP was stably overexpressed in MCF-7, the cells
became resistant to doxorubicin, daunomycin, and mitoxantrone, meeting criteria as a
multidrug transporter [47]. BCRP is also known as ABCP for its high placental
expression [48] and as MXR for mitoxantrone resistance [49]. Currently, P-gp, MRP1,
and BCRP are considered to be the three major “drug transporters” for their wide array of
substrates and their roles in MDR phenotypes seen in many cell lines/tumors. Their
substrates are not limited to chemotherapeutic agents as they can transport many other
drugs including antiviral agents, antibiotics, and antimalarials (a concise list of their
substrates is reviewed in ref. [50]).
Through the search of human expressed sequence tag (EST) database, the number
of ABC proteins grew rapidly [44, 51]. Because of the role of P-gp and MRP1 as
mutidrug transporters, other MDRs (ABCB full transporters) and MRPs have been
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extensively studied to identify clinically relevant substrates. Some were found to be
overexpressed in drug resistant cells (such as MRP4)[51, 52] and others were found to
confer drug resistance when ectopically overexrpressed in cells (for a list of drugresistant cell and transfection studies, see ref. [53]). There is a significant overlap in the
substrates among transporters from different subfamilies [50, 54], but there are substrates
that are characteristics of a certain subfamily. For example, many MRPs transport
nucleoside and cyclic nucleoside analogs. ABC transporters can also transport drug
metabolites such as glutathione or glucuronate conjugates or mono-, di-, or triphosphates.
Although not all drug transporters are upregulated in MDR cells, their ability to
transport a wide array of compounds underscores the importance of identifying
transporters for clinically used drugs. Not only do ABC transporters play a role in drug
resistance, they also have critical roles in drug distribution and drug toxicity. For
example, transporters may reduce drug efficacy by limiting the drug penetration into
target tissues or impairing absorption leading to sub-therapeutic drug concentrations. On
the other hand, reduced transporter function may increase susceptibility to adverse effects
by increasing drug concentrations leading to prolonged exposure. Some ABC transporters
have reduced activity secondary to non-synonymous single nucleotide polymorphisms
(SNP). SNPs have been identified that affect the function of P-gp, MRP1, and BCRP
(summarized in the ref. [55]). ABC transporters themselves can be drug targets given
their roles in MDR, and several P-gp inhibitors are on clinical trials [53]. However, their
physiological roles need to be determined to avoid any adverse effects.
1.2.2. Physiological Roles of ABC Transporters
In general, ABC transporters in the plasma membrane play an important role in
pumping toxic compounds out of the cell or in maintaining cellular homeostasis, whereas
transporters located on intracellular organelle membranes are involved in diverse
biological or metabolic processes. Cell membranes provide a first line of barrier to limit
the access of toxins into the cells or contain them in particular compartments within the
cells. They can also act as a barrier to maintain a chemical gradient of compounds that do
not readily cross the lipid bilayers. ABC transporters expressed on the cell surface add
another layer of protection by actively pumping out toxins or metabolites. In accordance
with their protective role, ABC transporters are expressed at such sites as blood-brain
barrier (BBB), blood-placenta barrier, and luminal side of intestine, where the entry of
toxins is strictly limited due to deleterious effects they may have. Development of animal
models lacking ABC transporters has revealed unexpected but sometimes critical roles of
these transporters in normal physiology.
Many compounds including drugs ingested orally are absorbed from the intestinal
brush border membrane. Transporters such as P-gp/ABCB1, BCRP/ABCG2, and
MRP2/ABCC2 are expressed on the apical membrane of intestine and limit the
absorption of xenotoxins [28, 35, 56]. Increased oral availability of topotecan was
observed in BCRP knockout (KO) mice supporting the barrier function of BCRP at the

8

level of absorption [35]. Other transporters, such as obligate heterodimers of ABCG5 and
ABCG8 that limit sterol absorption [36, 57], are also expressed in the intestine. Even if
the compounds are absorbed in the intestine, they can still be metabolized by hepatic
cytochrome P450 enzymes for detoxification and excretion through the bile and urine.
The bile mainly consists of cholesterol, various bile acids generated in
hepatocytes from cholesterol, phospholipids, and bilirubin. Transporters located on the
canaliculus membrane directly contribute to the content of bile, since they pump their
substrates into the bile flow. Sinusoidal (basolateral) membranes of the hepatocytes come
directly in contact with the bloodstream allowing the cells to take up whatever was
absorbed at the intestine. They also provide a site for releasing the bile acid overload
during cholestasis when bile flow is blocked or for releasing essential compounds
generated in the hepatocytes, such as glutathione (GSH), to be circulated in the blood. As
the major site for detoxification of endo- and exogenous compounds, liver contains a
number of ABC transporters in order to move them across the membranes to other
compartments. To name a few, canalicular transporters include P-gp/ABCB1 [56],
BSEP/ABCB11 [58], MDR3/ABCB4 [59], MRP2/ABCC2 [28], and BCRP/ABCG2
[35], and sinusoidal transporters include MRP3/ABCC3 [60], MRP4/ABCC4 [61], and
MRP6/ABCC6 [62]. Many of the substrates for the canalicular transporters were
identified by analyzing bile contents from the knockout mouse models. For example, bile
collected from mdr2-/- mouse (MDR3/ABCB4) was completely devoid of phospholipids
highlighting the role of MDR3 as a biliary phospholipid transporter [59]. BSEP, as its
name stands for bile salt export pump, transports hydrophobic bile acids into bile [58],
which is then absorbed by intestine as part of the enterohepatic circulation. On the other
hand, MRP2/ABCC2 pumps glucuronide-, glutathione-, or sulfate-conjugated
compounds, which have become more hydrophilic than the original compound, into bile
to be removed from the system [28]. ABCG5 and ABCG8 have been implicated in
flipping the cholesterol from the inner to the outer leaflet of canalicular membranes
affecting biliary excretion of cholesterol and other sterols in a MDR3-dependent manner
[63, 64]. Basolateral transporters MRP3 and MRP4 have been shown to transport bile
acids, especially sulfated-bile acids, which cannot be handled by BSEP, into the blood
perhaps to alleviate the toxic effects of hepatic bile acid accumulation during cholestasis
[60, 61, 65]. The ABC transporters affect the fate of endo- and exogenous compounds
both at the levels of intestinal absorption and the hepatic elimination. Mutations in many
of these transporters are found to be the causes for human diseases. They are summarized
in Table 1.1.
Another compartment protected by numerous transporters is brain. Because of its
essential role in all animals, an entry of compounds into brain is limited by two barriers:
BBB and blood-cerebrospinal fluid (CSF) barrier (BCB). The BBB function is
maintained by the endothelium of brain capillaries; tight junctions between the cells do
not allow paracellular movement of compounds from blood to the brain, whereas apical
ABC transporters actively pump compounds into blood to limit their brain penetration.
Several apical ABC transporters are reported including P-gp/ABCB1 [21], MRP2 [66],
MRP4 [67], MRP5 [68], and BCRP [69]. Their role in BBB function was first identified
in mdr1a KO mice when the animals suffered neurotoxic side effects from ivermectin
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due to a 90-fold accumulation of the drug in the brain compared to the wild type mice
[21]. Similar observations were made using Mrp2 deficient TR- rats and anti-epileptic
drug [66], and Mrp4 KO mice and topotecan [67]. Apical localization of the transporters
was also confirmed using immunohistochemistry. The second barrier in the brain to limit
the uptake of the toxic compounds, BCB, is maintained by epithelial cells in the choroid
plexus. The apical surface comes directly in contact with CSF; therefore, the basolateral
transporters pump compounds into blood to prevent brain penetration. MRP1 and MRP4
have been shown to localize on the basolateral membranes in choroid plexus and to
contribute to the low etoposide [70] and topotecan [67] concentrations in CSF. P-gp
localizes at the apical membrane, thus is not responsible for lowering the drug
concentration at BCB [71]. Although the ABC transporters protect the brain from
xenotoxins providing two layers of barrier at BBB and BCB, they pose a major challenge
to treating disorders in the central nervous system (CNS) including brain tumor.
Therefore, it is critical to determine whether compounds are substrates for certain
transporters in order to increase the efficacy without increasing systemic adverse effects.
P-gp and BCRP inhibitors have been tested on pre-clinical models to increase brain
distribution of CNS-targeted drugs.
Protective roles of ABC transporters extend to other compartments including
materno-fetal interface where placental transporters prevent toxic agents from reaching
the fetus. Significant accumulation of such drugs as paclitaxel and topotecan was found
in mdr1a-/-/1b-/- and Bcrp-/- embryos respectively [35, 72]. Recent findings also implicate
a protective role of ABC transporters in stem cells [73, 74]. BCRP has been shown to be
a stem cell marker and pumps Hoechst 33342 dye out contributing to the side population
phenotype, which is used to isolate stem cells [74]. BCRP can also confer a survival
advantage for stem cells under low oxygen conditions known as hypoxia by removing
excess porphyrins and heme, which can damage membranes and other molecules [75].
All of the transporters described above that have the ability to pump out toxic
compounds are expressed at the plasma membrane. Most of the half transporters
belonging to B and D subfamilies reside on intracellular membranes and are involved in
diverse biological processes. Transporters associated with antigen processing (TAP) 1
and TAP2 (ABCB2 and ABCB3 respectively) localized on the endoplasmic reticulum
(ER) are important molecules in immune response [76, 77]. After an antigen is degraded
by proteasomes in the cytoplasm, TAP1/TAP2 heterodimers translocate the antigenic
peptide across the ER membrane. The peptide is then loaded onto major
histocompatibility complex (MHC) class I molecule, which can then present the antigen
to T cells at the cell surface [78]. Mutations in TAPs are linked to immunodeficiency [23,
24]. TAP-like (TAPL, ABCB9) is expressed in the lysosomal membrane [79] where it is
also thought to transport peptides [80]. Functions of other ABCB half transporters will be
described in later sections. Although their substrates are not fully understood,
peroxisomal transporters, ABCD subfamily members, are implicated in beta-oxidation of
fatty acids [81].
Among the ABC transporters (ABC proteins with MSDs), cystic fibrosis
transmembrane conductance regulator (CFTR, ABCC7), sulfonylurea receptor 1 (SUR1,
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ABCC8), and SUR2 (ABCC9) have unique roles in regulating ion concentrations. CFTR
was initially identified as a cystic fibrosis (CF) causing gene and was later found to
function as a low conductance Cl- channel [30, 82]. Three SUR proteins, SUR1, and two
splice variants of SUR2, SUR2A and SUR2B, are regulators of ATP-sensitive K+
channels involved in such processes as regulating insulin secretion and vascular tone
[83], and have no transport function identified to date.
1.2.3. ABC Transporters and Diseases/Phenotypes
About one third of known human ABC genes are associated with phenotypes
linked to a genetic defect [2]. Well known genetic disorders associated with ABC genes
include cystic fibrosis, retinal degeneration, and Dubin-Johnson syndrome (summarized
in Table 1.1., [2]). Variations in a single nucleotide (creating a non-synonymous change)
may be enough to produce deleterious effects. For example, a single nucleotide mutation
in ABCB7, which has been implicated in iron homeostasis and iron-sulfur cluster
formation, is linked to X-linked sideroblastic anemia and ataxia (XLSA/A) [26]. A wellcharacterized CFTR mutant, ∆F508 results from a 3-bp deletion to produce a deletion of
phenylalanine at position 508 [30]. This mutant cannot properly traffick to the plasma
membrane and instead is targeted for degradation at the ER [84]. Lack of sufficient
amount of CFTR, a chloride channel, at the membrane results in abnormal ion balance
and fluid transport in airway cells, which ultimately leads to CF. Cystic fibrosis is the
most common fatal genetic disease in Caucasians.
There are other SNPs or mutations reported in ABC genes that do not have severe
clinical manifestations but may have effect on the protein function. For example, a
mutation in P-gp gene will increase the sensitivity to drugs that are P-gp substrates. In a
subset of dogs of the collie breed, a severely truncated P-gp is produced as a result of a 4bp deletion in exon 4. In these dogs, insufficient activity of P-gp at BBB causes
sensitivity to ivermectin, a commonly used veterinary medicine for heartworm prevention
[21, 22, 85]. A SNP in ABCC11 gene was found to be associated with earwax type, wet
or dry [33]. Since ABCC11 is implicated in a cyclic nucleotide transport and has been
shown to transport some drugs [86], it will be of an interest to see if the dry ear wax
phenotype correlates with sensitivity to ABCC11 substrates. Phenotypes that can be seen
immediately give an advantage over genotyping when considering tailor made
therapeutics. Also, sensitivity to a particular drug may indicate impairment in some ABC
transporters and, therefore, care should be taken when administering drugs that are
substrates for such transporters.
1.2.4. Architecture of ABC Transporters
It is generally accepted that two sets of MSDs, each containing six
transmembrane (TM) helices, and NBDs form a functional transport unit, with one set of
MSD plus one NBD being considered a core unit (Fig. 1.1.)[87]. Introduction of a
mutation in a single NBD is sufficient to abrogate transport activity, underscoring the
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importance of having two functional NBDs [88], even though ATP binding and
hydrolysis at two NBDs are often not equivalent. When full transporters are separated
into two core units (N- and C-terminal halves), co-expression of both halves is able to
reconstitute transport activity, suggesting that functional transport units are not required
to be in a single polypeptide [89, 90]. In accordance, half transporters, which only contain
a single core unit, either homodimerize as has been suggested for ABCG2 [91] or
heterodimerize as seen in ABCG5/ABCG8 [57] and TAP1/TAP2 [92]. For obligate
heterodimers, co-expression of two genes is essential for proper folding and maturation
[57, 93]. Higher oligomers are reported for some transporters, although their
physiological roles remain elusive [91]. Domains that are important for dimer formation
have been reported [94-96], but it is likely that more than one is responsible for the stable
dimer formation. Recently reported structure of bacterial ABC multidrug transporter,
Sav1866, also shows that TM helices from two MSDs intertwine to form two wings,
which open up to release its substrates [97]. Crosslinking studies showed similar TM
helices arrangement for P-gp [98].
MSDs have been implicated in substrate binding, thus share a low homology
among transporters, whereas NBDs, which are responsible for binding and hydrolyzing
ATP, are highly conserved [42]. As shown in Fig. 1.1., some MRPs contain an additional
set of MSD, termed MSD0 with five TM helices, and some ABCB half transporters (i.e.,
TAPs) contain three to five additional TM helices [99]. While these domains may have
an effect on basal transport activity [100], they have been shown to act as docking sites
for interacting proteins [101] or regulatory domains for transport [102]. In ABCG
subfamily, the arrangement of MSD and NBD is opposite from the other ABC
transporters such that N-terminal NBD is followed by MSD. From biochemical and
kinetic studies, it has been shown that ABC transporters are capable of binding multiple
compounds simultaneously as seen in other multidrug binding proteins [103-107].
Although the use of UV-crosslinking of photoactivatable ligands and mutagenesis studies
have also identified residues that are involved in the drug binding [108, 109], the
structural evidence of substrate(s)-bound ABC transporters is required to fully understand
the precise drug binding site(s). Based on structural information from bacterial multidrug
binding protein QacR, the drug binding site is thought to contain a number of aromatic
residues and a couple of charged amino acid residues to neutralize charged compounds
[105, 106]. Also, the drug binding site contains several “mini-pockets” that can
accommodate different classes of drugs. These mini-pockets are continuous so that a
bulky compound can utilize more than one mini-pocket for binding [105]. Since the
substrate recognition is so complex, it is not feasible to predict substrate specificity based
on the secondary structures.
To understand the function of NBDs, extensive mutagenesis studies have been
performed on the conserved regions. In addition, soluble NBDs, unlike MSDs, are
crystallized and their structures have been determined with or without nucleotide bound
to them. NBD contains several characteristic domains including Walker A and B motifs,
signature motif, switch region, and A, D, and Q loops each playing a critical role in
nucleotide binding and/or hydrolysis (Fig. 1.2.). Both biochemical and structural studies
have shown that two functional NBDs are required to form functional ATPases and that
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Figure 1.2. Interaction between ATP and different motifs from two NBDs.
Mutagenesis studies as well structural data revealed interactions between an ATP
molecule and key residues in different motifs. Motifs on opposite sides of ATP represent
two NBDs. This diagram shows that an ATP molecule is sandwiched between two
NBDs. This explains the need for two NBDs in functional ABC transporters. Reprinted
from Molecular Cell, Vol 10(1), Smith, P.C., Karpowich, N., Millen, L., Moody, J.E.,
Rosen, J., Thomas, P.J., and Hunt, J.F., ATP binding to the motor domain from an ABC
transporter drives formation of a nucleotide sandwich dimer, p. 139-149, Copyright
(2002), with permission from Elsevier [110].
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two molecules of ATP are bound at the dimer interface. The requirement for NBD dimer
is readily understood by the observation that the Walker A and B motifs, switch region, A
and Q loops from one NBD and the signature motif and D loop from the other NBD all
contribute to make up the active ATPase [110]. The A-loop, an aromatic amino acid
located ~25 amino acid residues upstream of Walker A motif, stacks the adenine ring
from ATP, and the phosphates are stabilized by Walker A motif, whereas Walker B
contains a catalytic glutamate. The histidine residue from the switch region promotes
ATP hydrolysis by stabilizing the γ-phosphate and later the transition state [110, 111]. Qloop binds to catalytic water, where D-loop (for dimerization) binds to Mg2+ as well as
interacting with the catalytic water. The signature motif binds to γ-phosphate of ATP and
plays a critical role in disengaging the dimer after ATP hydrolysis. However, an
asymmetry in the NBD exists for many transporters. For TAP1/2, only one ATPase site
constitutes of consensus motifs, where the other ATPase site has degenerate motifs
implying that the consensus site is the primary site for ATP hydrolysis for substrate
transport [111].
The Sav1866 structure as well the TAP1 structure revealed a soluble linker
wrapped around the NBDs [97, 112]. In Sav1866, where the structure of the entire
molecule was solved, the cytoplasmic loops were shown to interact with NBDs possibly
transmitting information from NBDs to MSDs and vice versa [97]. Unexpectedly, the
cytoplasmic loops were found to reach over to the NBD from the other molecule, making
a twisted turn at the interface (Fig. 1.3.) [97].
1.2.5. Transport Mechanism
It has been shown that substrate translocation by ABC transporters requires ATP
molecules. However, the precise mechanism of the translocation and the role of ATP
binding and hydrolysis has been controversial. The initial model proposed by Senior et al.
[113] included ATP binding to an empty NBD, which stimulates hydrolysis of the other
ATP when a substrate is bound. This produces a change in affinity and results in the
release of the substrate to the other side. ADP is released, which then resets the
transporter to the high affinity state. The key points in this model are that only one ATP
is hydrolyzed per transport cycle and that the ATP hydrolysis alternates between two
NBDs. The other feature of this model is that the “power-stroke” which translocates
substrates comes from ATP hydrolysis. On the contrary, recent structural and
biochemical data favor the “ATP-switch” model, where ATP binding itself is the powerstroke [114]. In this model, substrate binding at high affinity site favors ATP binding to
NBDs, which results in the formation of closed dimer. The change in the NBDs is then
transmitted to MSDs inducing a conformational change to a low affinity state for
substrates and the outward opening of the TM helices. The substrate is then released and
the subsequent ATP hydrolysis followed by ADP and Pi release disengage the NBD
dimer, resetting the transporter to a high affinity site. Accordingly, Sav1866 structure
shows that the nucleotide binding stabilizes the outward opening of TM helices [97].
Substrate binding has been shown to induce a conformational change in many
transporters [115] and relatively high KM for ATP in isolated NBDs may imply that the
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Figure 1.3. Bacterial ABC transporter Sav1866 structure.
Backbone of the homodimeric Sav1866 is shown in ribbon or coil representation with
nucleotides bound at cytoplasmic NBDs. Yellow and turquoise represent each subunit in
the dimer. A. This view shows membrane-embedded TM helices forming outward wings.
TM helices from two subunits are intertwined to form the wings. Grey region indicates
the position of predicted lipid bilayers. B. The protein is rotated 90˚ around the vertical
axis with resprect to A. TM helices in turquoise subunit are numbered. C. Close up view
of the NBDs. This view shows the cytoplasmic loops coming from turquoise TM helices
reach NBDs from subunits as colored in red. TM, transmembrane helices; NBDs,
nucleotide binding domains; ICL, intracellular loops (between TM helices); N-ter, amino
terminus; C-ter, carboxy terminus. Reprinted by permission from Macmillan Publishers
Ltd: Nature (Dawson, R.J. and Locher, K.P., Structure of a bacterial multidrug ABC
transporter. Nature, 2006. 443(7108): p. 180-185.), copyright (2006) [97].
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changes in MSDs promote ATP binding.
1.2.6. Regulation of ABC Transporters
ABC transporter expression is regulated by transcription, translation, and
degradation and their function is regulated by proper localization, post-translational
modification, and/or interaction with other proteins. As xenobiotic pumps, many ABC
transporters are known to be induced by their substrates and other xenobiotics that can
activate nuclear receptors such as pregnane X receptor (PXR), constitutive androstane
receptor (CAR), farnesoid X receptor (FXR), and peroxisome proliferators-activated
receptor gamma (PPARγ) [116]. A number of bile acids activate FXR, which in turn
induces BSEP/ABCB11, a bile acid transporter in the liver canaliculis [117, 118]. PXR
activators induce P-gp and MRP2, whereas CAR activators are known to induce P-gp,
MRP2, and MRP4 [116]. These nuclear receptors regulate expression of many
metabolizing enzymes namely cytochrome P450’s, which can generate conjugated
compounds that are substrates for the transpoters. CAR activation results in the
coordinated upregulation of both Mrp4 and Sult2a1 [119]. Sult2a1 catalyzes the
formation of sulfated steroids and bile acids, which can be removed from hepatocytes
especially during cholestasis [119]. Because many drugs can induce or inhibit
transporters, the drug-drug interaction may cause unexpected adverse effects. Stress
stimuli are also known to induce ABC transporters in order to protect the cells. For
example, BCRP/ABCG2 confers a survival advantage to cells during hypoxia and is
induced by the binding of hypoxia-inducible factor 1 (HIF-1) to the hypoxia response
element under hypoxic conditions [75]. Epigenetic changes such as promoter methylation
and histone modification have also been shown to correlate with mRNA levels of
transporters [120-123].
The usage of alternate promoters and splicing has been implicated in mRNA
expression levels and tissue distribution of BCRP/ABCG2 [124-126]. In addition,
alternative splicing has been reported for many of the ABCC subfamily members [127130]. Some alternatively spliced isoforms still produce functional proteins; however,
some isoforms contain premature termination codons and are targeted for nonsensemediated mRNA decay [129, 130].
The expression of the ABC transporters can also be regulated at the translational
level. A synonymous SNP in the coding region of P-gp has been shown to decrease the
rate of translation resulting in a slightly different folding of the protein [131]. Incorrect
folding of the protein also does not leave ER and is targeted for degradation as seen with
CFTR ∆F508 [84]. The mechanisms and the signals for sorting transporters to proper
membranes such as apical and basolateral membrane, are also being extensively studied;
however, much is unknown about signals that target transporters to correct membranes.
Protein stability also plays a role in determining the levels of functional transporters.
Post-translational modifications such as N-glycosylation of BSEP/ABCB11 and P-gp
have been shown to affect protein stability or the proper trafficking [132, 133]. Other
ABC transporters are modified by glycan attachment. However, the role of N-
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glycosylation on ABC transporters has been somewhat inconclusive. For BCRP, the
glycosylation has been shown not to affect its localization, expression, or transport
activity [134].
Functional regulation of CFTR/ABCC7 has been extensively studied and the
phosphorylation by PKA has been shown to activate its channel function. CFTR has also
been shown to have several interacting partners through the C-terminal PDZ domain.
Functional and physical coupling to the G protein coupled receptors (GPCR) such as β2
adrenergic receptors [135] and type 2 lysophosphatidic acid receptor [136] have been
reported. Since CFTR is activated by cyclic adenosine monophosphate (cAMP), the close
proximity to a cAMP transporter, MRP4 through PDZ interaction attenuates its channel
activity [137]. TAP1/2 also function in a macromolecular complex called peptide-loading
complex, which consists of tapasin, MHC class I, ERp57, β2-microglobulin, and
calreticulin [138]. Further, interaction with other proteins may influence cell surface
internalization and recycling as seen in GPCRs.
1.3. Half Transporters in ABCB Subfamily
The ABCB subfamily is unique among the other subfamilies because it contains
both full and half transporters. There are six half transporters in this subfamily, ABCB2,
B3, and B6-B10. ABCB2 and B3 (TAPs) reside in the ER and ABCB9 (TAPL) in the
lysosomes, and they are all involved in the translocation of peptides into the respective
organelles. ABCB6-B8 and B10 localize at the mitochondria and are involved in other
biological processes, although ABCB10 has been speculated to play a role in transporting
peptides out of the mitochondria. Phylogenetic analysis revealed that within the B
subfamily, there are three subgroups: the one containing full transporters, the second one
containing ABCB2, B3, B8, B9 and B10, and the third one containing B6 and B7 [138].
It is not surprising that four transporters involved in peptide transport are clustered in one
group even though their cellular localizations vary.
TAP1/2 are one of the well-characterized transporters beside the three major drug
transporters. The TAP1 NBD has been crystallized and numerous mutagenesis studies
showed mechanisms and kinetics of peptide transport cycle [111, 112, 139-144].
Moreover, the unique topology of TAPs with additional N-terminal TM helices was
shown to be important for their interaction with tapasin, which is essential for forming
the peptide-loading complex [99, 101]. TAPs translocate antigenic peptides into ER
lumen to load them onto MHC class I molecules. Peptide-loaded MHC class I molecules
are then dissociated from TAPs and present the antigen to T cells at the cell surface
[138].
ABCB9 was initially identified from rat as a transporter homologous to TAP1 and
TAP2 and was thus named TAP-like (TAPL) [145]. Mouse and human ABCB9 was later
cloned and found to localize in lysosomes by immunofluorescence microscopy and
gradient centrifugation [79]. Lysosomal localization of ABCB9 was confirmed by
another group, which also showed ATP-dependent peptide transport into lysosomes by
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functional ABCB9 [146]. Unlike TAP1/2, ABCB9 is not involved in the antigen
presentation by MHC class I and has been shown to homodimerize [80, 147]. Although
the implication of its lysosomal localization is unclear, because ABCB9 expression is
induced when monocytes differentiate into dendritic cells, professional antigen presenting
cells, its role in delivering nuclear or cellular peptides to MHC class II has been
suggested [146].
ABCB8 was the first mammalian mitochondrial ABC transporter to be
characterized [148], but three other mammalian mitochondrial ABC transporters,
ABCB6, B7, and B10, have been reported to date. Immunofluorescence studies showed a
co-localization of ABCB8 with MitoTracker, a mitochondria marker. Also, a faster
mobility in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) when expressed in
intact cells compared to in vitro translated samples suggested a cleavage of a signal
peptide. Indeed, the N-terminal of ABCB8 was sufficient for mitochondrial targeting of
green fluorescent protein (GFP). Although the authors were not able to purify inner and
mitochondrial outer membranes, the presence of a cleavable signal peptide led to a
speculation that ABCB8 is in the mitochondrial inner membrane [148]. The substrates for
ABCB8 are yet to be identified; however, it has been implicated in the cellular protection
against oxidative stress [149]. Reduction of ABCB8 protein by small interfering RNA
(siRNA) in neonatal rat cardiomyocytes leads to a loss of mitochondrial membrane
potential. On the other hand, overexpression of ABCB8 protects cells from hydrogen
peroxide-induced mitochondria dysfunction [149]. ABCB8 has been found in a large
cross-linked complex containing four mitochondrial proteins although the physiological
implication of the complex is unclear [150]. Regardless of what the substrates may be,
ABCB8 is likely to be involved in the maintenance of mitochondrial membrane potential.
1.3.1. ABCB7/Atm1p
Saccharomyces cerevisiae Atm1p is the first mitochondrial ABC transporter to be
identified and stands for ABC transporter of mitochondria [151]. Atm1p contains a
functional mitochondrial targeting sequence at its N-terminus and is localized at the inner
membrane. The NBD of Atm1p has been suggested to reside in the matrix and, therefore,
this transporter is considered to move its substrates into the intermembrane space. It
forms a homodimer and a mutation in the conserved lysine residue in the Walker A
domain disrupts dimer formation [94]. Yeast cells lacking atm1 display slow growth with
the increased oxidative stress considered to result from the mitochondrial free iron
accumulation [152, 153]. Increased sensitivity to the oxidative stress can be attributed
partly to the reduced catalase activity. Although a decrease in the heme containing
molecules is seen in the ∆atm1 cells, including catalase and cytochomes, Atm1p is not
considered a heme transporter [151, 152, 154]. In yeast cells where heme biosynthesis is
defective, addition of heme rescues the slow growth phenotype, whereas heme does not
affect the cells lacking atm1, suggesting that reduced levels of heme is a secondary effect
in ∆atm1 cells [151]. On contrary, Atm1p has been shown to be involved in the
generation of cytosolic [Fe-S] proteins [155]. Whether Atm1p directly transports the [FeS] cluster or not has not been shown. However, purified Atm1p reportedly shows ATPase
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activity stimulated by molecules containing sulfhydryl groups, especially by peptides
containing cysteine residues [156]. If Atm1p substrates include peptides containing
sulfhydryl groups, then it is not surprising that another mitochondrial peptide transporter
mdl1 was identified as a high copy suppressor of atm1 to partially rescue the sensitivity
to oxidative stress [157]. Mdl1p may be able to transport some of Atm1p substrate
peptides in the absence of Atm1p. Regardless, it is clear that Atm1p plays a role in the
iron homeostasis in S. cerevisiae. Recent findings in zebrafish show that [Fe-S] clusters
are required for heme biosynthesis suggesting there is an intricate relationship between
the two iron-containing molecules [158].
Mammalian ABCB7 was identified as the functional ortholog of yeast Atm1p
[159], and mutations in this gene result in a partial loss of the function causing XLSA/A
[26, 160, 161]. ABCB7 essentially has the same characteristics as the yeast Atm1p; it
localizes to the mitochondria, contains a mitochondrial targeting sequence at the Nterminus, and restores growth, catalase activity, and normal iron level in ∆atm1 strain
when overexpressed [159]. Abcb7 null mice were embryonic lethal indicating that this
gene is essential for development [162]. This explains the fact that only partial loss of
protein function is observed in XLSA/A patients because fetuses harboring the mutations
resulting in a complete loss of function will not be viable. This underscores the
importance of [Fe-S] clusters as cofactors to many enzymes including respiratory chain,
citric acid cycle, ribosome assembly, and amino acid synthesis [156]. Many of the tissuespecific conditional Abcb7 KO mice were not viable with the exception of the liverspecific KO animals. Using the liver from these animals, the role of Abcb7 in the
biogenesis of cytosolic [Fe-S] clusters was confirmed [162]. Total liver iron was
increased in the knockout mice but there was no significant mitochondrial iron
accumulation. Because cytosolic [Fe-S] clusters were unavailable, the cells responded as
if they were under iron depletion (e.g., IRP binding to IRE was increased).
Mitochondrion appears to be the site for regulating iron homeostasis; it is critical for [FeS] cluster formation, four of the eight steps in heme biosynthesis take place in the
mitochondria, and mitochondrial ferritin is able to store free iron without damaging
mitochondrial components. Therefore, it is not surprising that heme synthesis is altered in
Abcb7 KO animals or cells as a consequence to altered iron homeostasis especially in
mitochondria. Increased ratio of zinc protoporphyrin IX (PPIX) to heme was observed in
the blood from chimeric inducible-Abcb7 KO animals [161] and increased PPIX was
observed in the HeLa cells treated with ABCB7 siRNA [163]. These studies suggested
that heme biosynthesis was not defective in these systems because PPIX is the
penultimate product before forming heme and ferrochelatase catalyzes the insertion of
both iron and zinc atoms into PPIX. Moreover, the mitochondrial ferritin-bound iron was
significantly reduced in HeLa cells treated with ABCB7 siRNA even in the presence of
mitochondrial iron accumulation, suggesting this pool of accumulated iron is inaccessible
to ferrochelatase for heme biosynthesis [163]. Iron is an essential molecule to life and,
therefore, its usage is tightly regulated.
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1.3.2. ABCB10/ABC-me
ABCB10/ABC-me, named for its mitochondrial localization and erythroid
expression, was originally identified as a GATA-1 target gene [164]. GATA-1 is a
transcription factor essential for erythropoiesis, and it regulates many erythroid selective
genes. ABCB10 expression in the sites of definitive hematopoiesis, such as fetal liver and
adult bone marrow, also supported the potential role of ABCB10 in red cell development
[164]. Dimethylsulfoxide (DMSO), a known inducer for erythroid maturation, increased
ABCB10 mRNA expression in murine erythroleukemia (Mel) cells. Moreover, the rate of
hemoglobin synthesis was greatly increased during DMSO-induced differentiation in Mel
cells stably expressing ABCB10 [164]. However, the overexpression of ABCB10 in the
absence of DMSO did not result in the spontaneous differentiation of Mel cells or
increased hemoglobin synthesis; therefore, it is likely that ABCB10 facilitates the
DMSO-induced cell differentiation and may require other regulatory proteins/pathways
[164]. ABCB10 contains a mitochondrial targeting signal at its N-terminus and localizes
to the inner membrane with NBD in the matrix [164-166]. This orientation suggests
ABCB10 pumps its substrates from matrix into the intermembrane space. ABCB10 has
been shown to homodimerize and possibly form an oligomer [165]. The involvement of
ABCB10 in hemoglobin biosynthesis and its mitochondrial localization suggested that
ABCB10 might play a role in heme biosynthesis. As mentioned earlier, heme
biosynthesis occurs both in the matrix and the cytoplasm. Therefore, although the
substrates for ABCB10 are yet to be identified, it was suggested that ABCB10
transported heme or its precursors into the intermembrane space [164]. Heme, the end
product in the heme biosynthesis, reduced ABCB10 mRNA suggesting a feedback
mechanism to regulate heme biosynthesis [164]. However, the precise role of ABCB10 in
erythropoiesis still needs to be determined.
From a phylogenetic analysis, yeast Mdl1p has been suggested to be an ABCB10
homolog [138]. They both localize to mitochondrial inner membranes and form
homodimers [165, 167]. Mdl1p exports peptides generated by m-AAA protease in the
matrix into the intermembrane space [167]. Because ABCB10 clusters with other
mammalian peptide transporters ABCB2, B3, and B9, it may have a role in peptide
transport; however, no direct evidence has been presented.
1.3.3. Identification of ABCB6 (PRP/UMAT/MTABC3)
As is the case with many ABC transporters, ABCB6 has more than one name.
When a partial sequence of rat ABCB6 was cloned in 1997 as a gene upregulated during
hepatocarcinogenesis, it was named P-gp-related protein (PRP) [168]. Full-length rat
ABCB6 was cloned in 1998 and was identified as a half transporter [169]. Northern blot
showed a ubiquitous expression of this transporter with testis having the highest
expression level [169]. Both studies pointed out a high homology between rABCB6 and
Schizosaccharomyces pombe heavy metal tolerance-1 (hmt1) protein. Hmt1 localizes to
the vacuoles in yeast and confers a heavy metal resistance by sequestering toxic metals
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into vacuoles [170]. Whether ABCB6 has a functional homolog in yeast or not is yet to
be determined.
In 2000, Mitsuhashi et al. cloned full length human ABCB6 (named MTABC3)
and showed its mitochondrial localization using immunofluorescence microscopy and
subcellular fractionation [171]. ABCB6 gene is comprised of 19 exons and is located at
chromosome 2q36. Ubiquitous expression of ABCB6 in many tissues including skeletal
muscle, heart, brain, kidney, and pancreas, was confirmed. Because of its mitochondrial
localization, ABCB6 was introduced into a yeast strain partially defective in Atm1p
function to determine whether it can complement the function of Atm1p. Exogenous
ABCB6 expression lowered amounts of free iron in mitochondria to a level comparable
to Atm1p-expressed cells. However, neither ABCB6 nor Atm1p overexpression restored
a normal level of mitochondrial iron. Moreover, a non-functional mutant of ABCB6 with
mutations in the Walker A motif partially rescued ∆atm1 phenotypes in these cells. These
results suggested that the effect of ABCB6 expression on the iron level was unlikely to be
transport-function dependent. Therefore, even though ABCB6 was suggested to be a
homolog of Atm1p in this particular study [171], functional studies and the phylogenetic
analysis clearly suggest that ABCB7, not ABCB6, is the true ortholog of Atm1p [159].
Taken together, ABCB6 appears to be involved in the mitochondrial iron homeostasis
and possibly cell proliferation but its function remains largely unknown.
1.3.4. Transcriptional Regulation of ABCB6
Genome-wide analyses of transcription factor binding have led to a series of
discoveries of previously unknown targets. In short, chromatin immunoprecipitation is
performed using an antibody against a transcription factor of interest. Coimmunoprecipitated genomic DNA is analyzed by microarray to determine the identity of
the sequences. ABCB6 promoter has been shown to potentially bind at least three
transcription factor complexes from such studies. Li et al. showed that Myc/Max complex
binds to the promoter of ABCB6 in Burkitt’s lymphoma to possibly activate gene
expression [172]. Similarly, p130 and E2F4 complex was found to bind to the promoter
of ABCB6 under growth arrest condition to repress the expression [173]. Interestingly,
they also identified nuclear respiratory factor-1 (NRF1) binding site in the promoter of
ABCB6 [173]. NRF1 has been shown to regulate the expression of genes involved in
mitochondrial function and biogenesis [174]. These findings suggest that ABCB6 is
induced in rapidly proliferating cells and its expression may be coordinated with the
expression of other mitochondrial proteins.
1.4. Heme Biosynthesis
Heme is an essential molecule and is, therefore, synthesized in almost all living
cells with few exceptions. Organisms such as Caenorhabditis elegans, which does not
have the capability of synthesizing heme, rely on exogenous heme for maintaining
hemoproteins and iron homeostasis [175]. The tetrapyrrole structure, a backbone

21

structure of heme and porphyrins, is seen in other molecules including chlorophyll and
vitamin B12. Heme, an iron-containing PPIX, acts as a cofactor for numerous proteins
involved in a variety of cellular processes. The production of heme is highest in the
erythroid cells to sustain the robust hemoglobin synthesis, which is required for oxygen
transport [176]. Another tissue with a high rate of heme biosynthesis is liver, which
requires heme for the detoxifying enzyme cytochrome P450. In other tissues/cell types,
heme is involved in many essential biological processes including respiratory chain,
oxidative metabolism, and signal transduction [176]. Heme also regulates gene
expression at transcription and translation level and affects protein stability and
localization [176].
Even though heme is required for cellular functions, excess heme and porphyrins
result in unfavorable outcomes [177]. First, iron in the heme can generate free hydroxyl
radicals via Fenton’s reaction, which damage cellular components such as DNA and
membranes. Second, protoporphyrins are photosensitizers releasing singlet oxygen
radicals in a light-dependent manner. Given the cytotoxic effects of iron, heme and
porphyrins, cells tightly regulate heme biosyntheis by coordinating it with the synthesis
of apo-hemoproteins. Additionally, removal of excess intracellular heme and porphyrins
by cell surface transporters alleviates the cytotoxic effects. Heme catabolism by heme
oxygenases into iron and biliverdin, which is ultimately converted to bilirubin, is another
mechanism to eliminate excess heme.
1.4.1. Heme Biosynthesis and Diseases
The first step in heme biosynthesis takes place in the mitochondrial matrix,
followed by four steps in the cytoplasm, and the subsequent three steps in the
mitochondria complete the process (Fig. 1.4.)[176]. In humans, all eight enzymes
involved in the heme biosynthesis have been cloned. The heme biosynthesis pathway is
essentially the same in all human cells; however, because of the robust heme production
in erythroid cells, erythroid-specific enzymes, either encoded by different genes or
alternatively spliced, and different regulatory mechanisms exist in these cells. The first
step in heme biosynthesis, the condensation of glycine and succinyl-CoA, is catalyzed by
5-aminolevulinate synthase (ALAS). In non-erythroid cells, the formation of ALA is the
rate-limiting step. However, the translation of erythroid-specific ALAS2 protein is
regulated by the availability of iron via the iron regulatory proteins/iron responsive
element (IRP/IRE) pathway, which involves iron-sensing machinery through [Fe-S]
clusters [179]. Therefore, in erythroid cells, the iron availability for heme is the ratelimiting step. The end product of the pathway, heme, can also inhibit ALAS2 by binding
to the enzyme and retaining it in the cytoplasm. ALA formed in the mitochondrial matrix
is then transported into the cytoplasm by a yet to be identified carrier(s), and is converted
to a monopyrrole, porphobilinogen (PBG), by ALA dehydratase (ALAD). Subsequent
enzymatic reactions by PBG-deaminase (PBGD), uroporphyrinogen III synthase
(UROS), and uroporphyrinogen decarboxylase (UROD) form coproporphyrinogen III
(CPgenIII). CPIII is then translocated into the intermembrane space of mitochondria, a
step suggested to involve an energy-dependent carrier [180, 181]. CPgenIII oxidase in the
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Figure 1.4. Heme biosynthesis pathway.
First step in heme biosynthesis occurs in mitochondria, followed by four steps in the
cytosol. Coproporphyrinogen III oxidase and protoporphyrinogen IX oxidase are located
in the mitochondrial intermembrane space, whereas the last step in heme biosynthesis, an
insertion of an iron molecule into protoporphyrin IX, takes place in the matrix. Adapted
by permission. http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT
_9465.1, accessed September 14, 2008 [178].
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intermembrane space then converts CPgenIII to protoporphyrinogen IX. The next
enzyme in heme biosynthesis is protoporphyrinogen IX oxidase, an integral membrane
protein in the mitochondrial inner membrane with the active site facing the
intermembrane space. This enzyme generates the penultimate product, PPIX. The
insertion of ferrous iron into PPIX is catalyzed by ferrochelatase, which is anchored to
inner membrane with its active site facing the matrix. How PPIX translocates across the
inner membrane is not fully understood. Mitochondrial iron used for heme is thought to
be imported by mitoferrin in the inner membrane, a member of solute carrier family
(SLC), specifically SLC25 subfamily [182]. At least three pools of iron have been
suggested to exist in the mitochondria: iron stored in mitochondrial ferritin, [Fe-S]
clusters, and a pool of iron readily available for ferrochelatase [163]. Further
investigation is required to understand the precise mechanisms of iron trafficking and
distribution in the mitochondria as well in the cytoplasm.
Every enzyme in the heme biosynthesis pathway has been shown to cause
diseases when mutated, underscoring the importance of heme in mammals. Mutations in
ALAS2 cause XLSA and mutations in the rest of the enzymes lead to various types of
porphyria [176, 183]. Clinical manifestations include photosensitivity, neuropathy, and
acute porphyric attack but the severity of porphyrias varies among the subtypes. Also,
sites of porphyrin overproduction and accumulation characterize two subgroups within
the seven porphyrias. Defects in UROS and ferrochelatase lead to erythroid porphyrin
overproduction, whereas defects in the other five enzymes result in hepatic porphyrias
[183]. Although the porphyrias are inherited disorders, acute porphyria attacks can be
induced by drugs and other chemicals.
1.4.2. Compounds That Interfere with Heme Biosynthesis
Chemically-induced porphyrias are the results of disturbance in the heme
biosynthesis pathway. The most commonly used inhibitor for heme biosynthesis in the
laboratory is succinylacetone (SA), which inhibits ALAD. However, there are several
clinically relevant compounds that interfere with the heme biosynthesis pathway.
Barbiturate drugs such as phenobarbital have been known to precipitate porphyria attacks
in individuals with hereditary hepatic porphyrias by inducing ALAS1, which exaggerates
porphyrin overproduction [184]. Heavy metals are also known to have effects on heme
biosyntheis pathway and cause urinary porphyrin excretion in exposed individuals.
Therefore, heavy metal contamination in the soil is a serious problem in some parts of the
world. For example, lead toxicity amounts to clinical manifestations of porphyria attacks,
because it binds to ALAD, and inhibit the enzyme [185]. Lead also inhibits the action of
ferrochelatase by competing for the binding of iron. The ratio of zinc PPIX to heme
increases under lead poisoning, which has been implicated in bone marrow toxicity [186].
Another heavy metal linked to porphyria is arsenite. Aresenite likely increases urinary
porphyrin excretion by inhibiting PBGD and UROD [187]. Alcohol has also been linked
to disruptions in heme biosynthesis, which may be due to an apparent pleiotropic
inhibition of the following enzymes: ALAD, UROD, CPO, and ferrochelatase [188].
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1.4.3. Photodynamic Therapy
The cytotoxic photosensitizing characteristics of porphyrins have proven to be
quite useful when it comes to detecting and treating some tumors. Malignant tissues
readily take up and accumulate porphyrins upon administration of ALA. In primary
malignant glioma, accumulation of porphyrins produced a red fluorescence under specific
wavelength (375-440 nm) to allow tumor visualization during surgery [189]. Fluorescing
and non-fluorescing samples from the perimeter of the tumor were histologically
determined to confirm that the porphyrin fluorescence was an excellent tumor marker.
The ability of tumor to accumulate porphyrins is the cornerstone of photodynamic
therapy [190]. Porphyrin-derivatives or ALA, are administered as photosensitizers, and
activated by light at specific wavelength to induce cell death in tumor lesions. Underlying
mechanisms of selective porphyrin accumulation and overproduction in tumor cells have
not been fully understood. It is speculated that the rapidly proliferating tumor cells have a
higher requirement for energy; thus, rate of heme biosynthesis is increased as with other
cellular metabolisms.
1.5. Heme and Porphyrin Transporters
The requirement for heme and porphyrin transporters at least in the plasma
membrane and the mitochondrial membranes is evident. Iron is essential to life and is
absorbed at the intestinal membranes as inorganic iron or as the more bioavailable heme
iron from myoglobin and hemoglobin. The uptake of heme at the cell surface has been
suggested to be carrier-mediated [191]. On the other hand, heme biosynthesis occurs in
mitochondria and cytoplasm, requiring movement of porphyrin precursors across
mitochondrial membranes. This transmembrane movement has been suggested to involve
energy-dependent processes but the identity of protein(s) responsible for such processes
remains elusive. Moreover, exporters at the cell surface have been shown to play an
important role in alleviating cytotoxic effects of heme and porphyrins under certain
conditions. It is also possible that heme transporters on other organelle membranes exist
in order to compartmentalize heme/porphyrins or to provide heme for apo-homoproteins.
Porphyrins and heme readily associate with cellular membranes due to their
hydrophobic heterocyclic moieties, which may contribute to their damaging effects on
membranes when activated. However, translocation from the outer leaflet of the lipid
bilayer to the inner leaflet is a much slower process because of their anionic propionate
side chains [192]. Therefore, the simple diffusion of heme precursor across the
mitochondrial membranes is not sufficient to sustain the need for robust heme production
in the erythroid cells. Accordingly, the presence of an energy-dependent transport of
porphyrins into mitochondria has long been suggested [180, 193]. Similarly, the activity
of heme uptake at the plasma membrane has also been documented [191].
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1.5.1. Heme Importer: Heme Carrier Protein 1
Heme carrier protein 1 (HCP1) was identified as heme importer from mouse
duodenum where majority of heme absorption occurs [194]. HCP1 is a member of the
major facilitator superfamily (MFS, SLC46A1) and localizes to the plasma membrane.
Overexpression of HCP1 has been shown to increase heme uptake into cells [195]. In
addition, HCP1 translocates from cytosol to the brush border membrane of enterocytes
under iron-deprived conditions, suggesting that its function is regulated by cellular
demand for iron to prevent possible iron overload [194]. Interestingly, Qiu et al. reported
that HCP1 is a bona fide proton-coupled folate carrier by determining that mutation in
this gene is the underlying basis for hereditary folate malabsorption [196]. Therefore, the
physiological role of HCP1 on iron or heme homeostasis warrants further investigation.
1.5.2. Heme/Porphyrin Exporters
As mentioned in the earlier section, Bcrp is a porphyrin exporter at the cell
surface [75]. Bcrp null mice showed photosensitivity due to an accumulation of
photosensitizer pheophorbide a (PhA), a chlorophyll-metabolite, which has a tetrapyrrole
backbone [35]. Not only does BCRP act as an exporter to remove exogenous porphyrins
but it also acts to remove excess endogenous porphyrins [75]. Compounds with
tetrapyrrole structures, but not a monopyrrole such as PBG, competed for specific
binding of BCRP to hemin-agarose. These results suggested that tetrapyrrole backbone
was important for substrate recognition [75]. Interestingly, BCRP also transports folate,
illustrating the possible substrate overlap between HCP1 [197]. Due to activation of
porphyrin biosynthesis, heme precursors are increased under hypoxic conditions, similar
to levels of BCRP [75]. BCRP function is required to removes excess porphyrins under
hypoxia protect cells from their cytotoxic effects.
Another heme exporter was identified through the search for feline leukemia
virus, subgroup C (FeLV-C) cell surface receptor. FeLV-C receptor (FLVCR) was cloned
and characterized as a member of MFS located at the cell surface [198]. Cats with FeLVC develop severe anemia due to red cell aplasia; therefore, Quigley et al. speculated that
FLVCR might play a role in red cell differentiation. Accordingly, overexpression of
FLVCR reduced heme accumulation into cells and the inhibition of FLVCR function by
FeLV-C interfered with erythroid differentiation [199]. From these results, it was
suggested that FLVCR acts as an “overflow valve” in erythroid cells to prevent the
accumulation of free heme when there is not enough globin synthesized. Definitive proof
was presented, however, when they showed that Flvcr null mice were embryonic lethal
and lacked definitive erythropoiesis [200]. Flvcr null embryos had pale livers and lacked
Ter119 positive cells, suggesting an arrest in erythropoiesis. The role of FLVCR as a
heme exporter in differentiating erythroid cells emphasizes the importance of highly
regulated heme biosynthesis and its utilization. Even in differentiating erythroid cells,
where robust heme production is required, heme levels need regulation in order to avoid
their cytotoxic and potentially deleterious effects on the terminal differentiation.
However, FLVCR mRNA decreases as the erythroid cell differentiation proceeds [199],
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supporting the idea that FLVCR is required at the critical point where globin synthesis
has not caught up with the heme biosynthesis.
In order to study the function of FLVCR, Flvcrflox/flox;Mx-Cre was generated, where
interferon administration induces a Cre recombinase activity. In this system, Flvcr gene
can be knocked out in postnatal mice [200]. The mice developed severe hyperchromic
macrocytic anemia with iron accumulation in such cells as splenic macrophages,
hepatocytes, and duodenal enterocyes. Cardiomegaly and splenomegaly were also
observed as consequences of severe anemia. These results indicate that FLVCR is
involved in systemic iron homeostasis through heme transport. In human, FLVCR is
highly expressed in tissues with high iron and/or heme traffick: duodenum, liver, spleen,
uterus, placenta, and cultured macrophages. By using the iron-storage protein, ferritin, as
a read-out, FLVCR was implicated in heme efflux from macrophages after they engulf
senescent red blood cells. These results suggest that heme acquired from red blood cells
may be recycled instead of being broken down by heme oxygenases. Also, Keel et al.
speculate that the expression of FLVCR in the liver is important for biliary excretion of
heme, although this claim needs further investigation.
1.5.3. Intracellular Porphyrin Transporters
Much is unknown about intracellular movement of heme and porphyrins.
However, few proteins have been shown to either bind heme or be involved in the
transport of heme or porphyrin. In many instances, porphyrin binding and transport are
indistinguishable, making the interpretations of the data somewhat difficult.
Peripheral-type benzodiazepine receptor (PBR), originally identified as
benzodiazepine receptor on the mitochondrial outer membrane, has been suggested to act
as a porphyrin transporter. PPIX and CPIII were shown to compete for the binding of
radiolabeled benzodiazepine to PBR [201]. Moreover, PBR expression was induced
during the erythroid differentiation [202]. Taken together, Taketani et al. proposed a role
for PBR in erythroid differentiation, acting as a porphyrin transporter in the heme
biosynthesis pathway. There is no evidence to support this claim since direct porphyrin
transport has not been shown to date. It is still possible that PBR is a porphyrin-binding
component of a protein complex that trasnlocates porphyrins across the membrane.
Members of SLC25 subfamily are mitochondrial carrier proteins involved in the
movement of many solutes and metabolites that are critical for mitochondrial functions.
SLC25A11, also known as 2-oxoglutarate carrier (OGC), is a mitochondrial inner
membrane protein, which transports 2-oxoglutarate into mitochondria in exchange for
malate. Imported 2-oxoglutarate is then used for various metabolic pathways in the
mitochondria including citrate cycle. Using metalloporphyrin-conjugated beads, OGC
was identified as a porphyrin binding protein [203]. Hemin, PPIX, and CPIII all
competed for 2-oxoglutarate uptake into mitochondria suggesting a competitive binding
on OGC [203]. In addition, mitochondrial porphyrin uptake was inhibited by 2oxoglutarate [203]. These findings led to a conclusion that OGC is a porphyrin
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transporter involved in the movement of porphyrins from the intermembrane space to
matrix. However, OGC inhibitor was only able to inhibit the porphyrin accumulation by
50% and the highest inhibition observed was about 40% at the highest dose of 2oxoglutarate used (50 mM) [203]. The relevance of porphyrin transport by OGC in the
heme biosynthesis pathway still needs to be determined.
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CHAPTER 2. CHARACTERIZATION OF ABCB6 AS A PORPHYRIN
TRANSPORTER*
2.1. Introduction
Heme, an iron-containing porphyrin, is an essential molecule and has a crucial
role in oxygen transport as a cofactor for globins [176]. However, heme plays important
roles in many other biological processes such as metabolism and detoxification of
biological compounds and xenotoxins (cytochromes, catalase, and peroxidase), oxidative
phosphorylation (complex II-IV), signal transduction (adenylate and guanylate cyclases),
and transcription regulation (N-PAS2 and Bach1) [176]. Heme also regulates a number
of genes by affecting transcription, translation, protein targeting, and protein stability
[205-209]. Even though heme and pophyrins are fundamental to life, excess heme and
porphyrins have cytotoxic effects; iron in heme produces hydroxyl radicals via Fenton’s
reaction and porphyrins absorb light and generate oxygen radicals [177]. Therefore,
intracellular levels of heme and porphyrin are tightly regulated. Deleterious effects of
dysregulated heme biosyntheis are readily seen in the forms of various porphyrias or
sideroblastic anemia [176, 183].
Heme biosynthesis takes place in two subcellular compartments: the mitochondria
and the cytoplasm [176]. The first step in heme biosynthesis is the formation of ALA
from glycine and succinyl-CoA in the mitochondrial matrix. The next step occurs in the
cytoplasm where ALA is converted to a monopyrrole, PBG, followed by three enzymatic
reactions to yield CPgenIII. The last three steps in heme biosynthesis take place in the
mitochondria with an iron insertion into PPIX being the last step. The tetrapyrrole ring
backbone, which can be found in heme and its precursors, chlorophyll and its
metabolites, and vitamin B12, in CPgenIII is lipophilic and readily associates with the
membrane. However, the anionic propionate side chains in CPgenIII make it a challenge
to cross lipid bilayers with a simple diffusion [192]. In accordance, the uptake of the
CPgenIII has been suggested to involve an energy-dependent active transport [193]. Even
though several proteins have been identified to transport porphyrins across the plasma
membrane (BCRP, FLVCR, and HCP1), the intracellular porphyrin transport process
remains elusive [210]. However, the high rate of heme biosynthesis, especially in
erythroid cells, requires such transporter(s) at the mitochondrial membrane to actively
move heme precursor, CPgenIII, into the intermembrane space in order to facilitate the
heme biosynthesis.
The ABC transporters translocate a wide array of compounds across the plasma
membrane and the subcellular membranes in an ATP-dependent manner. Because of their
ability to transport numerous compounds, ABC transporters play a role in many
*
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biological processes including antigen presentation, insulin secretion, and cellular
differentiation [2]. Physiological roles of many ABC transporters have been identified by
the usage of KO animal models or by tissue distribution pattern. Variations in ABC
transporters are the underlying molecular basis for a number of human disorders and
phenotypes, which have also led to the identification of their function. The core unit of
ABC transporters is composed of one MSD and one NBD aligned in tandem. Functional
transporters require two of such units; MSDs composed of six TM helices bind
substrates, whereas the NBDs bind and hydrolyze ATP molecules, thus, energizing the
transport cycle. Full transporters contain two core units in a single polypeptide, whereas
half transporters only contain one unit and are required to homo- or hetero-dimerize in
order to exert their function. Half transporter ABCB6 localizes to the mitochondria [171],
where three other members of the ABCB subfamily reside. ABCB6 is induced during
liver regeneration and is associated with the mitochondrial iron homeostasis [168, 171].
The mitochondria play an important role in cellular iron homeostasis because they are the
sites for heme biosynthesis, [Fe-S] cluster formation, and iron storage in mitochondrial
ferritin [156].
In order to understand the physiological role of ABCB6, other authors in this
study examined the tissue distribution pattern of ABCB6. They demonstrated that
ABCB6 mRNA is highly expressed in human fetal liver and mouse embryonic liver by
Northern blot and in situ hybridization, respectively. In addition, database search revealed
that ABCB6 is highly expressed in both human bone marrow and CD71+ early erythroid
cells. These expression patterns suggested that ABCB6 is highly expressed in the site of
erythropoiesis or in the cells with robust heme production. Increased cellular porphyrin
levels by an addition of ALA or hemin, which is reduced to heme intracellularly, induced
ABCB6 both at mRNA and protein levels. Taken together, we hypothesized that ABCB6
plays a role in intracellular trafficking of porphyrins. ABCB6 was also induced in the
animal models with altered heme/porphyrin levels; increased splenic erythropoiesis by
phenylhydrazine treatment or increased cellular PPIX levels due to a lack of Bcrp gene
both induced Abcb6 mRNA. These results further indicated that ABCB6 responds to an
enhanced heme biosynthesis or increased cellular porphyrins. In order to gain insights
into the role of ABCB6 in heme biosynthesis, the precise localization of ABCB6 in
mitochondria was determined by separating mitochondrial inner and outer membranes on
sucrose gradient. ABCB6 exclusively co-localized with the mitochondrial outer
membrane markers. Further, proteinase K digestion on the intact mitochondria expressing
C-terminally tagged ABCB6 showed that the C-terminus of ABCB6 localizes in the
cytoplasm. These results indicated that ABCB6, localized to the mitochondrial outer
membrane, transports its substrates into the intermembrane space from the cytoplasm.
Given its location, direction of transport, and induction by elevated intracellular
porphyrins, we hypothesized that ABCB6 may be the elusive porphyrin transporter that
shuttles the heme precursor into the mitochondria. In accordance with this hypothesis,
binding of ABCB6 to the agarose-conjugated hemin was confirmed.
My contribution to this study was to determine the substrates for ABCB6 and to
show that the elevated levels of PPIX in ABCB6 overexpressing cells require functional
ABCB6. By confirming that ABCB6 forms a homodimer, we were able to characterize
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ABCB6 function using cells overxpressing ABCB6 alone. The affinity for different heme
precursors as well as other tetrapyrroles was tested to determine the structural
requirement for ABCB6 binding. To definitively show that the transport function of
ABCB6 was responsible for the observed effect of ABCB6 on heme biosynthesis, I
generated human erythroleukemia cell line, K562, stably expressing either wild-type
ABCB6 or non-functional Walker A ABCB6 mutant (in later chapter, this mutant is
shown to be defective in ATP binding). Using these cell lines, other authors of this study
showed that the ATP-dependent mitochondrial hemin uptake was seen only when the
wild-type ABCB6 was expressed. I also showed that the substrate-stimulated ATPase and
the elevated basal PPIX levels required a functional ABCB6. Other authors then showed
that de novo heme biosynthesis was also upregulated in cells that expressed functional
ABCB6. These findings indicate that ABCB6 is a porphyrin transporter that shuttles
heme precursors into the mitochondria from the cytoplasm, thereby facilitating heme
biosynthesis.
2.2. Experimental Procedures
2.2.1. Cell Culture and Transfection
NIH3T3 and K562 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 4500 mg/L glucose supplemented with 10% FCS, 2 mM Lglutamine, and penicillin and streptomycin (Gibco) in the presence of 5% CO2 and
humidified atmosphere. Cells were transfected using LipofectAMINE Plus (Invitrogen)
according to the manufacturer’s protocols. Cells were plated on 6 well-clustered dish at 3
x 105 cells/well 24 hours prior to transfection. For each transfection, 1 µg of indicated
plasmid was used unless otherwise noted.
To obtain K562 cells stably expressing ABCB6-V5 or ABCB6-K629G-V5,
pcDNA3.1-hABCB6-V5 or pcDNA3.1-hABCB6-K629G-V5 was introduced into K562
cells by electroporation. Cells were selected with G418 for two weeks before the
expression of ABCB6 was tested by immunoblotting.
2.2.2. Site-Directed Mutagenesis
Plasmids pcDNA3-hABCB6-FLAG and pcDNA3.1-hABCB6-V5-His were
designed to express human ABCB6 with C-terminal tags, FLAG or V5 respectively. A
point mutation was introduced into pcDNA3.1-hABCB6-V5-His using a Quikchange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) and primers (K629G; sense, 5’GTGGGCCCATCTGGGGCAGGGGGGAGCACAATTTTGCGCCTGCTG-3’,
antisense, 5’-CAGCAGGCGCAAAATTGTGCTCCCCCCTGCCCCAGATGGGCCCAC-3’, G508L; sense 5’- CAGAACCTGGTGATTGGGCTCCTGCTCCTCGCCGGCTCCCTGCTTTG-3’, antisense, 5’- CAAAGCAGGGAGCCGGCGAGGAGCAGGAGCCCAATCACCAGGTTCTG-3’, G512L; sense 5’- GATTGGGCTCGGGCTCCTCGCCC-
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TCTCCCTGCTTTGCGCATACTTTG-3’, antisense, 5’- CAAAGTATGCGCAAAGCAGGGAGAGGGCGAGGAGCCCGAGCCCAATC-3’, G508,512L; sense, 5’- GAACCTGGTGATTGGGCTCCTGCTCCTCGCCCTCTCCCTGCTTTGCGCATAC-3’,
antisense, 5’- GTATGCGCAAAGCAGGGAGAGGGCGAGGAGCAGGAGCCCAATCACCAGGTTC-3’, D641A; sense, 5’- GCCTGCTGTTTCGCTTCTACGCCATCAGCTCTGGCTGCATCCG-3’, antisense, 5’- CGGATGCAGCCAGAGCTGATGGCGTAGAAGCGAAACAGCAGGC-3’, D650A; sense, 5’- GCTCTGGCTGCATCCGAATAGCTGGGCAGGACATTTCACAGGTGAC-3’, antisense, 5’- GTCACCTGTGAAATGTCCTGCCCAGCTATTCGGATGCAGCCAGAGC-3’). All genes were thoroughly
sequenced after mutagenesis.
2.2.3. Immunoblotting and Immunoprecipitation
Twenty-four hours after transfection, cells were washed with phosphate buffered
saline (PBS) and harvested into 1 ml ice-cold PBS containing 1x protease inhibitor
cocktail (Complete EDTA free, Roche). Cell suspensions were centrifuged at 1,500 x
rpm for 4 min at 4˚C. Cells were resuspended in Buffer A (50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 10% glycerol, and 1 x protease inhibitor cocktail (Roche)), and then
sonicated. After the final concentration of 1% NP-40 was added, the cells were
solubilized for 60 min at 4˚C with a constant rocking, followed by centrifugation at 3,000
x rpm for 5 min at 4˚C to remove cell debris. The supernatant was further subjected to
immnoblotting or immunoprecipitaiton after protein concentration was measured by
Bradford method (Protein Assay, Bio-Rad Laboratories, Inc.). Final concentration of 1 x
Laemmli sample buffer (Bio-Rad) was added to the supernatant for immunoblotting. For
immunoprecipitation, the lysate was incubated with an anti-V5 monoclonal antibody
(Invitrogen) or an anti-FLAG antibody monoclonal antibody (M2, Sigma) at 1:150
dilution, and Protein A Sepharose beads (Amersham Pharmacia Biotech., Liscataway,
NJ) for 2 hr. The samples were washed twice with wash buffer (Buffer A containing 1%
NP-40), and then Laemmli sample buffer was added to the immnoprecipitates. For
immnoblotting, proteins were separated on 10% SDS-PAGE and transferred onto
nitrocellulose membrane (Schleicher & Schuell Biosciences, Inc., Keene, NH). The
membrane was blocked with 10% skim milk in PBS-T (PBS and 0.1% Tween 20) and
then incubated with an anti-V5 polyclonal antibody (MBL, Japan) or anti-FLAG
polyclonal antibody (Sigma). The blot was washed with PBS-T, and then incubated with
horseradish peroxidase-conjugated anti-rabbit IgG F(ab’)2 fragment (Amersham
Pharmacia Biotech.). The blot was washed again with PBS-T and detection was
performed with enhanced chemiluminescence detection (ECL, Amersham Pharmacia
Biotech.).
2.2.4. Crude Mitochondria Preparation
K562 cells were pelleted, washed with PBS, and resuspended in resuspension
buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 7.6), and 1 x protease
inhibitor cocktail (Roche). After 10 min incubation on ice to allow the cells to swell, they
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were broken with type B Dounce homogenizer. 2.5 x membrane stabilizing buffer (525
mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl (pH 7.6), and 2.5 mM EDTA) was
added to the homogenate to a final concentration of 1 x. The samples were centrifuged at
1,300 x g for 5 min at 4 ˚C to remove cell debris and nuclei. The supernatant was further
centrifuged at 17,000 x g for 15 min at 4˚C to pellet mitochondria.
2.2.5. Hemin-Agarose Pull-Down Assay
Cell lysates prepared from NIH3T3 cells transiently expressing ABCB6-V5 or
ABCB6-K629G-V5 as described above were incubated with hemin-agarose for 30 min at
24˚C. For competition assays, indicated compounds were preincubated with the lysates
for 5 min prior to an addition of hemin-agarose. The resin was washed for three times
with wash buffer, and the proteins were eluted using 1 x Laemmli sample buffer
containing β-ME. ABCB6 bound to hemin-agarose was analyzed by immunoblotting.
2.2.6. ATPase Activity Measurement
The vanadate-sensitive ATPase activity in the crude mitochondria isolated from
K562, K562-ABCB6-Flag, K562-ABCB6-V5, and K562-ABCB6-K629G-V5 (Walker A
mutant) was measured by the colorimetric assay as described previously [211]. The
isolated mitochondria preparations containing 30 µg of protein were incubated with
indicated concentrations of CPIII (prepared in methanol) or PBG (prepared in ddH2O),
and the reaction was started with the addition of 3.3 mM MgATP. The vanadate-sensitive
CPIII- and PBG-stimulated ATPase activities were detected and calculated as the release
of inorganic phosphate (nmol Pi released/min/mg protein). Then the ATPase activity was
expressed as a fold change relative to the basal vanadate-sensitive ATPase activity. The
values are average of two to four measurements ± S.E.M.
2.2.7. Cellular PPIX Measurements
Cellular PPIX levels were measured by flow cytometry. Cells were harvested by
centrifugation, washed and resuspended in PBS. The PPIX fluorescence was measured
using a Vantage flow cytometer (BD Biosciences) in which the excitation wavelength
was set at 405 nm and the emission filter was set at 695/40 nm.
2.3. Results
2.3.1. ABCB6 Homodimerizes
Half transporters need to either homo- or hetero-dimerize in order to exert their
functions; however, whether ABCB6 homodimerized had not been determined. We
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postulated that ABCB6 functions as a homodimer because of two findings: i)
overexpression of ABCB6 alone in cells elevated PPIX levels and ii) three other known
mitochondrial ABC transporters localize in the inner mitochondrial membrane and,
therefore, are unlikely to dimerize with the mitochondrial outer membrane ABCB6. To
test if ABCB6 homodimerized, co-immunoprecipitation using differently tagged ABCB6
was performed. ABCB6-Flag and ABCB6-V5 were transiently co-expressed in NIH3T3
cells and lysates prepared. Anti-V5 or anti-Flag antibody was used to immunoprecipitate
V5- or Flag-tagged ABCB6, respectively, and Flag- or V5-tagged ABCB6 in the
immunocomplex was analyzed by immunoblotting (Fig. 2.1.). Both V5- and Flag-tagged
ABCB6 were found in the immunoprecipitates when anti-Flag antibody was used to
immunoprecipitate ABCB6-Flag indicating that ABCB6-V5 and ABCB6-Flag interact.
Similar results were obtained when anti-V5 antibody was used to immunoprecipitate
ABCB6-V5. These results indicate that ABCB6 homodimerizes and suggest that it does
not require a heterodimeric partner.
To determine the function of ABCB6, we then developed mutant ABCB6 and
focused on a domain that has been reported to affect either dimerization and/or function.
Substitution of the conserved lysine residue in the Walker A motif in the NBD impairs
transport activity of many ABC transporters [212, 213]. Further, previous studies have
shown several consequences of the substitution of this residue in half-transporters
including the loss of stable homodimer formation of Atm1p [94], the decreased targeting
of BCRP to the plasma membrane [214], and the loss of ATP binding by TAP1 [212].
We generated a mutant ABCB6 construct in which the conserved lysine residue is
substituted with a glycine residue. Differently tagged wild-type and Walker A mutant
ABCB6-K629G were transiently transfected in NIH3T3 cells in the indicated
combinations (Fig. 2.2.). Co-immunoprecipitation using anti-Flag antibody showed that
the Walker A mutant both homodimerizes and heterodimerizes with wild-type ABCB6.
ABCB6 contains two other motifs that have been shown to affect the packing of
α-helices of membrane proteins or homodimerization of yeast protein. Therefore, we next
tested the contribution of these two motifs in ABCB6 dimerization. In several membrane
proteins, the GXXXG motif is suggested to be important in the packing of α-helices in
transmembrane regions [215-217]. Based upon studies showing a conserved GXXXG
was important for BCRP transport activity [95], we also evaluated the contribution of this
motif to ABCB6 homodimerization. There are four GXXXG motifs present in ABCB6;
therefore, in order to select GXXXG motif that may reside in the membrane-spanning
domain, transmembrane α-helix regions in ABCB6 were predicted using three programs,
SOSUI, TopPred, and TMHMM [218-220]. All three programs predicted only the
GXXXG at amino acid residues 508 through 512 to be in an α-helix. Thus, point
mutations were introduced to substitute Gly508 and Gly512 with leucine residues. Yeast
protein Gts1p homodimerizes through a region (DXXXGXXXXD) that is very similar to
a downstream region of the Walker A motif of several ABC transporters [221]. Also, the
binding of C-terminal regions of yeast ABC transporter Mdl1p to Gts1p was lost or
diminished when the aspartate residues were substituted with alanine residues [221].
ABCB6 contains a highly similar sequence at the downstream of the Walker A motif.
Thus, Asp641 and Asp650 were substituted with alanine residues to evaluate the role of
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Figure 2.1. Homodimerization of ABCB6.
NIH 3T3 cells were transiently transfected with plasmids encoding ABCB6-FLAG and
ABCB6-V5. Twenty four hours after transfection, cell lysates were prepared and were
incubated with anti-FLAG (M2) or anti-V5 antibodies and with Protein A Sepharose
beads. The immunoprecipitates were washed twice with wash buffer, and the samples
were analyzed by immunoblotting. TL: total lysate.
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Figure 2.2. Mutation in the Walker A motif does not affect ABCB6 dimerization.
NIH 3T3 cells were transiently transfected with plasmids encoding ABCB6-FLAG,
ABCB6-V5, or indicated K629G mutants. The immunoprecipitation was performed as
described in the Fig. 2.1.
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this motif in ABCB6 dimerization. NIH3T3 cells were transiently co-transfected with
ABCB6-Flag and mutant constructs as indicated. Anti-Flag antibody was used to
immunoprecipitate ABCB6-Flag from lysates and the interaction between mutant
ABCB6 proteins and wild type ABCB6 was analyzed by immunoblotting using anti-V5
antibody (Fig. 2.3.). As shown in Fig. 2.3, all the mutants co-immunoprecipitated with
wild type ABCB6 indicating that neither of the motifs are critical for ABCB6
dimerization. Moreover, the substrate binding was retained in G508/512L mutant as
shown by the hemin-agarose pull-down assay (Fig. 2.4.). Therefore, GXXXG motif is
unlikely to affect the packing of TM helices, unlike BCRP where transport activity was
abolished [95].
2.3.2. Interaction between ABCB6 and Heme Is Disrupted by Tetrapyrroles
ABC transporters translocate structurally different classes of compounds;
however, the substrate specificity cannot be predicted from the amino acid sequence at
present due to little structural information and thus, needs to be tested directly by
determining binding affinity or by measuring transport activity. Other authors of this
study showed that ABCB6 binds to hemin conjugated to agarose beads. The binding was
specific because a naturally occurring splice variant of ABCB6, which lacks 50 amino
acids but still localizes to mitochondria, did not bind to hemin-agarose. Therefore, I next
tested whether other compounds with a tetrapyrrole ring would displace ABCB6 from
hemin-agarose (Fig. 2.5.). Cell lysates were prepared from NIH3T3 cells transiently
expressing ABCB6-V5 and were incubated with indicated compounds before heminagarose pull-down assays. Notably, CPIII, an oxidized form of heme precursor CPgenIII
that needs to be shuttled into the mitochondria from the cytoplasm, was most potent in
displacing ABCB6 from hemin-agarose. Commercially available CPIII was used instead
of physiologically relevant CPgenIII because CPgenIII is readily oxidized to CPIII in
normal conditions. Another heme precursor, PPIX, also competed for binding to ABCB6
at a higher concentration. On the other hand, PBG, a monopyrrole heme precursor, had
no effect on ABCB6 binding to hemin-agarose even at the highest concentration tested
(80 µM). PhA, a chlorophyll metabolite with a tetrapyrrole backbone, was effective in
displacing ABCB6 from hemin-agarose at 10 µM, whereas vitamin B12, a tetrapyrrole
ring with a bulky side chain, was not, even at the highest concentration. These results
show that ABCB6 preferentially binds compounds with a tetrapyrrole structure with
anionic propionate side chains.
2.3.3. ABCB6 Transports Porphyrins in an ATP-Dependent Manner
Transport cycles by ABC transporters are fueled by ATP hydrolysis. The
transport process by ABC transporters begins with the binding of their substrates at
MSDs and ends with the stimulation of ATPase activity at NBDs resetting the transporter
for the next cycle. Because various porphyrins bind to ABCB6, we next tested whether
they can stimulate ATPase activity of ABCB6 and if they are transported into isolated
mitochondria in an ATP-dependent manner. Since a mutation of the conserved lysine
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Figure 2.3. GXXXG and the D(X)8D domains are not critical for the dimerization.
NIH 3T3 cells were transiently transfected with plasmids encoding ABCB6-FLAG,
ABCB6-V5, or indicated mutants, and immunoprecipitation was performed as described
in Fig. 2.1. All the mutants interacted with ABCB6. TL, total lysate.
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Figure 2.4. Walker A mutant and GXXXG mutant bind hemin-agarose.
Hemin-agarose pull-down assay was performed using lysates prepared from NIH3T3
cells transiently transfected with indicated plasmids. TL, total lysate.
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Figure 2.5. CPIII, PPIX, and PhA displace ABCB6 from hemin-agarose.
Cell lysates from NIH3T3 cells transiently transfected with ABCB6-V5 were preincubated with indicated amounts of compounds prior to hemin-agarose pull-down
assays. ABCB6 bound to hemin-agarose was analyzed by immunoblotting using anti-V5
antibody. The incubation with CPIII, hemin, PP IX, and PhA (tetrapyrroles) decreased
the amount of ABCB6 in hemin-agarose pull-down fraction, whereas, vitamin B12 and a
monopyrrole, porphobilinogen had no effect. CPIII; coproporphyrin III, PP IX;
protoporphyrin IX, PBG; porphobilinogen, PhA; pheophorbide a, Vit B12; vitamin B12.
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residue in the Walker A motif impairs the transport activity of many ABC transporters,
we decided to use the Walker A mutant, ABCB6-K629G-V5 as a control in these
experiments. I generated K562 cell lines that stably expressed either ABCB6-V5 or
ABCB6-K629G-V5 using G418 selection and selected for clones that expressed
comparable amounts of proteins. Crude mitochondrial preparations from these cell lines
were tested for ABCB6 and the mutant protein and the results indicate the mutant protein,
as well as the wild-type ABCB6, is enriched in this mitochondrial fraction (Fig. 2.6.).
Vanadate-sensitive ATPase activity was measured in these mitochondrial preparations as
a release of inorganic phosphates using a colorimetric assay. CPIII-stimulated ATPase
activity was observed with mitochondria expressing ABCB6 but not with those
expressing the Walker A mutant protein (Fig. 2.6.). Further, other authors of this study
showed that the uptake of 55Fe-labeled hemin by mitochondria expressing ABCB6 was
ATP- and temperature-dependent suggesting that the transport requires ATP hydrolysis.
The transport activity was abolished in the mitochondria expressing the Walker A
mutant, which retained the heme-binding ability (Fig. 2.4.), further supporting that
ABCB6 transports porphyrins into mitochoncria in an ATP dependent manner. A
tetrapyrrole, CPIII, but not a monopyrrole, PBG, competed for hemin uptake into
mitochondria. Taken together, CPIII showed a strong competition for binding of heminagarose to ABCB6, stimulated ATPase activity, and inhibited hemin uptake into
mitochondria.
2.3.4. ABCB6 Increases the Rate of Porphyrin Biosynthesis
ABCB6 is induced by both erythroid differentiation and increased intracellular
porphyrin levels. Because ABCB6 levels appear to be coordinated with heme
biosynthesis, we next tested the role of ABCB6 in heme biosynthesis. Using K562 stable
cell lines, I was able to show an elevated basal PPIX levels in cells expressing the wildtype ABCB6 compared to K562 parental cells or cells expressing the Walker A mutant
(Fig. 2.7.). To determine whether the higher PPIX accumulation was due to an increased
rate of de novo heme biosynthesis in ABCB6 expressing cells, other authors of this study
determined the amount of radiolabeled glycine incorporated into porphyrins. In both
mouse and human erythroid cell lines, Mel and K562, respectively, cells expressing
ABCB6 exhibited higher rate of de novo porphyrin biosynthesis. In CHO-TRex system
where gene expression can be induced by the addition of tetracycline, ABCB6 expressing
cells had a higher rate of de novo heme biosynthesis compared to the Walker A mutant
expressing cells. A loss of one Abcb6 allele in 129/SVJ-derived embryonic stem (ES) cell
lines resulted in a lower PPIX levels compared to Abcb6+/+ cells when treated with ALA,
suggesting a lower porphyrin biosynthesis in cells lacking one Abcb6 allele.
2.4. Discussion
Previously, mitochondrial half transporter ABCB6 was implicated in cellular iron
homeostasis and was suggested to be the functional homolog of yeast Atm1p [171].
However, phylogenetic analyses and the functional studies showed that ABCB7 is the
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Figure 2.6. CPIII stimulates ATPase activity in ABCB6 expressing mitochondria.
A) Both wild type and the Walker A mutant are enriched in the crude mitochondria
fraction. Crude mitochondria preparations were isolated from K562 cells stably
expressing either ABCB6-V5 or the Walker A mutant using differential centrifugation
and analyzed by immunoblotting using anti-V5 antibody. B) Vanadate sensitive ATPase
activity was measured as inorganic phosphate release. Crude mitochondria preparations
from K562 cells stably expressing ABCB6 or the Walker mutant was incubated with
varying amounts of CPIII. The values are expressed as measurements ± S.E.M.
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Figure 2.7. ABCB6 expressing cells exhibit higher intracellular PPIX levels.
The intracellular PPIX levels in the K562 cells expressing vector, ABCB6 or the Walker
A mutant (ABCB6 MT) were measured by FACS analysis.
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functional orthlog of Atm1p [159]. Therefore, the physiological role and the substrates of
ABCB6 remained elusive. The high expression levels of ABCB6 in fetal liver and
erythroid-lineage cells, its mitochondrial localization, and coordinated gene expression
with heme biosynthesis and erythroid differentiation led us to identify the role of
ABCB6in heme biosynthesis. In this study, I showed that ABCB6 is a homodimer that
binds to various porphyrins and that its ATPase activity is stimulated by a porphyrin,
CPIII. Furthermore, generation of a cell line stably expressing the Walker A mutant
ABCB6 enabled us to distinguish porphyrin binding from the transport activity involving
ATP binding and hydrolysis. The elevated basal levels of PPIX were seen in cells
expressing wild type ABCB6 but not in the cells expressing the Walker A mutant
showing that the transport function of ABCB6 is required for the observed effect. Our
results suggest that ABCB6 is ideally located on the mitochondrial outer membrane to
transport a heme precursor, CPgenIII, into the intermembrane space to overcome a
possible rate-limiting step, thereby facilitating heme biosynthesis.
The affinity for porphyrins, mitochondrial uptake of hemin, and CPIII-stimulated
ATPase activity in ABCB6-expressing cells all demonstrate that porphyrins are ABCB6
substrates. The affinity of ABCB6 for heme-related porphryins was highest for CPIII,
followed by hemin, and then by PPIX. Especially, an oxidized form of a heme
intermediate CPgenIII, CPIII, displaced more than 90% of ABCB6 from hemin-agarose
at 10 µM. The monopyrrole PBG did not disrupt the interaction between ABCB6 and
hemin-agarose. Notably, a plant tetrapyrrole and a mitochondrial toxin, pheophorbide a
also displaced ABCB6 from hemin-agarose effectively. Generally, the ATPase activity of
ABC transporters is induced by a substrate binding. Therefore, the observation that
ATPase activity is induced in the CPIII-treated ABCB6 expressing mitochondria further
supports CPIII, and possibly other porphyrins as ABCB6 substrates. Further, the uptake
of hemin into ABCB6 expressing mitochondria conclusively shows that the porphyrins
are ABCB6 substrates. The temperature and ATP dependence of the hemin uptake
suggests that ATP hydrolysis fuels the transport cycle. Accordingly, the Walker A
mutant, which lacks ATPase activity, failed to transport hemin. Moreover, by using the
Walker A mutant, which still interacted with hemin-agarose, we excluded the possibility
that the increased 55Fe-hemin in the ABCB6 expressing mitochondria was simply due to
the binding of hemin to ABCB6 at the mitochondrial membrane. These results indicate
that heme and other porphyrins are substrates of ABCB6.
The basal PPIX levels are increased in ABCB6-expressing cells compared to the
vector cells, and accordingly the accelerated rate of de novo porphyrin biosynthesis was
confirmed. In contrast, cells expressing the Walker A mutant ABCB6 behaved much like
vector cells and no increase in the PPIX levels nor the de novo porphyrin synthesis was
observed. These results indicate that the effect of ABCB6 on heme biosynthesis is
dependent on its transport function. In this study, we showed that ABCB6 interacts with
porphyrins and localizes on the mitochondrial outer membrane. Furthermore, the Cterminal tail of ABCB6 resides in the cytoplasm, which strongly suggests that ABCB6
transports its substrates from the cytoplasm into the intermembrane space. Hemin uptake
by ABCB6-expressing mitochondria also indicates the same direction of transport. From
these results, we postulated that ABCB6 is an ideal candidate for shuttling the heme
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precursor, CPgenIII, into the mitochondria, thus facilitating the heme biosyntheis. The
proposed role of ABCB6 as a CPgenIII transporter explains the accelerated rate of heme
biosynthesis because moving the CPgenIII into the intermembrane space, where the next
enzyme in the pathway resides, may overcome the possible rate-limiting step. Moreover,
our finding that PPIX levels are lower in the Abcb6+/- ES cells after ALA treatment is
consistent with the role of ABCB6 in heme biosynthesis.Taken together, these results
strongly suggest CPgenIII as one of the physiological substrates for ABCB6.
ABCB6 homodimerizes, and therefore, is unlikely to require a heterodimeric
partner. This finding was important because some ABC half transporters form obligate
heterodimers and the co-expression of heterodimeric partner is required for the proper
localization and the function [57]. The overexpression of a single protein ABCB6 was
sufficient to increase the PPIX levels and enhance mitochondrial hemin uptake, which is
consistent with ABCB6 functioning as a homodimer. Several domains are reported to be
important for the dimerization of ABC half transporters or other membrane proteins. The
yeast ABC transporter Atm1p failed to form a stable homodimer when the conserved
lysine residue in the Walker A motif was mutated [94]. Another motif implicated in the
packing of α-helices, GXXXG, is studied in several membrane proteins including ABC
transporters [95, 215, 216]. Mutation of the GXXXG in BCRP did not impair dimer
formation, although its transport function was altered [95]. A domain that is similar to a
downstream region of the Walker A motif of several ABC transporters is a critical
domain for the homodimerization of the yeast protein Gts1p [221]. Moreover, the
mutation of the aspartate residues in the domain (DXXXGXXXXD) resulted in a loss or
a diminished interaction between C-terminal regions of yeast ABC transporter Mdl1p and
Gts1p [221]. Generation of mutant ABCB6 that is impaired in the dimer formation would
be useful to test whether the dimerization is required for substrate binding, localization,
and the function. All of the mutants tested (Walker A, GXXXG, and DXXXGXXXXD)
interacted with the wild type ABCB6 protein indicating that none of these domains are
critical for the homodimerization of ABCB6. However, it is possible that the multiple
domains are involved in the formation of a stable dimer and that a loss of one domain
does not immediately result in a lack of dimer formation. Furthermore, because the
conserved lysine residue in the Walker A motif and the DXXXGXXXXD motif are
located in the NBD, mutations in these domains may affect the formation of NBD dimer
rather than the overall dimerization, which may result in an altered ATP binding and
hydrolysis.
In this study, we demonstrate that the mitochondrial ABC transporter ABCB6 is a
porphyrin transporter on the mitochondrial outer membrane. Because ABCB6 positively
regulates heme biosynthesis, we speculate that ABCB6 transports CPgenIII into the
mitochondrial intermembrane space where it is then converted into PPgenIX. The
transmembrane movement of the anionic porphyrin CPgenIII has been suggested to
involve an ATP-dependent active transport. Therefore, ABCB6, ideally located on the
mitochondrial outer membrane, may be the elusive porphyrin transporter required to
overcome the possible rate-limiting step in heme biosynthesis. The coordinated
upregulation of ABCB6 during erythroid differentiation and elevated porphyrin
biosynthesis is consistent with its role in heme biosynthesis. ABCB6 may transport heme
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into the mitochondria in order to supply heme for mitochondrial hemoproteins, whereas
compartmentalization of porphyrins may protect plasma membrane and other cellular
components from their cytotoxic effects. Like other ABC transporters, we anticipate
ABCB6 to transport a wide array of substrates; however, the current finding on its
porphyrin transport and its role in heme biosynthesis delineates its unique physiological
role.
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CHAPTER 3. ABCB6 PROVIDES INSIGHTS INTO THE MECHANISM FOR
SUBSTRATE TRANSPORT BY ABC TRANSPORTERS
3.1. Introduction
ABC transporters constitute a large protein superfamily, which is involved in the
transport of a wide array of substrates including xenobiotics and biological metabolites
across lipid bilayers [2]. The transport of various drugs is the basis for the multidrug
resistance phenotype conferred by an overexpression of certain ABC transporters,
whereas many others are implicated in the homeostasis of biomolecules, thus being
identified as disease causing genes in many human disorders. For transport activity, ABC
transporters require two MSDs and two NBDs. Half transporters, which consist of one
NBD and one MSD, therefore, need to either homo- or hetero-dimerize in order to
reconstitute transport activity. MSDs, generally composed of six TM helices, function in
substrate binding and determine the substrate specificity. The transport of substrates by
ABC transporters is energy-dependent and is linked to ATP binding and/or ATP
hydrolysis at NBDs.
In order to understand how the transport cycle is driven by NBDs, extensive
biochemical and structural studies have been performed using mutants and nucleotide
analogs to trap ABC transporters in different states during the transport cycle. Crystal
structures of isolated NBDs demonstrated that ATP-bound NBDs form a stable dimer,
where two ATP molecules are sandwiched by the two NBDs, providing the basis for the
requirement of two NBDs [110]. The NBDs are highly conserved among ABC
transporters and contain motifs such as Walker A and B, ABC signature, H and Q loops
[111]. The structures of isolated NBDs showed that ATP is bound by Walker A and B
motifs from one NBD and by ABC signature motif from the other [110]. Substitution of
the conserved lysine residue in the Walker A motif impaired ATP binding in some and
ATP hydrolysis in other ABC transporters [111, 212, 213, 222, 223]. On the other hand,
substitution of the conserved glutamate residue in the Walker B motif abolished ATPase
activity and subsequent release of ADP and Pi to confirm its role in ATP hydrolysis, thus
making this mutation useful when studying the structure of nucleotide-bound NBD [213].
The position of ATP between two NBDs explains the requirement for having two
functional NBDs to complete the transport cycle including ATP hydrolysis. Previous
studies suggest that the two NBDs are required for ATP binding and hydrolysis but are
not equivalent in some transporters, i.e., one NBD has a higher affinity for ATP and other
has a higher ATPase activity. This seems to be the case for some full transporters such as
ABCC1 [222], as well as half transporters that form heterodimers including
TAP1/ABCB2 and TAP2ABCB3 [111]. However, for Mdl1, a homodimeric
mitochondrial half transporter, such asymmetry does not appear to exist and the ATP
binding and hydrolysis occur in a stepwise manner [224].
A number of studies have established a coordinated action between MSDs and
NBDs in the substrate translocation by ABC transporters. Although there may be some
variations among different ABC transporters, the transport cycle is initiated upon binding
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of a substrate(s) to the MSDs, followed by ATP binding or ADP to ATP exchange at the
NBDs. It has been proposed that the subsequent ATP hydrolysis provides the energy to
translocate the substrate to the other side of the lipid bilayers [113, 115]. However, recent
biochemical and structural studies have implicated another mechanism for ATP-driven
substrate transport [97, 114]. Sometimes referred to as “ATP switch model,” the model
postulates that MSDs alternate between high-affinity state and low-affinity state for a
substrate and that the ATP binding and ATP hydrolysis trigger the conformational
changes to allow for releasing the substrate and resetting the transporter, respectively
[114]. A substrate binds to the MSDs at a high-affinity substrate site. ATP binding to the
NBDs induces a formation of a closed NBD dimer, which is coupled to conformational
changes in the MSDs resulting in a switch to a low-affinity substrate binding state, thus
translocating the substrate. Subsequent ATP hydrolysis disengages the NBD dimer,
thereby resetting the ABC transporter to a high-affinity state to start a new transport
cycle. Indeed, studies show that ATP binding to transporters such as Pgp induces a
conformational change as shown by different patterns of tryptic digestion [225]. In
addition, radiolabeled ligand binding assays have shown that MRP1 adapts a low-affinity
substrate site in the presence of nucleotides [226]. However, much of the structural
studies regarding nucleotide-bound NBDs have used isolated NBDs so how the changes
in NBDs transmit the information to MSDs is speculative [110, 111]. Variations appear
to exist within the two proposed transport models among the transporters. Nevertheless,
understanding transport mechanism is important to develop approaches to block
transporter functions. Since some half transporters confer resistance to drug therapy,
namely ABCG2/BCRP, it is important to understand the transport mechanism in half
transporters that form homodimers, which would have homologous NBDs. ABCB6 is
another half-transporter, shown to be a homodimer, and is localized to the mitochondrial
outer membrane. ABCB6 transports heme precursors/porphyrins into mitochondria,
thereby facilitating heme biosynthesis [204]. Since ABCB6 binds to heme conjugated to
agarose beads, it is an ideal model to study substrate binding and also the transport
mechanism.
In this study, we used ABCB6 and its Walker A lysine mutant to determine the
effect of nucleotide binding on substrate affinity. The conserved lysine residue in the
Walker A motif is critical for ATP binding and /or hydrolysis of ABC transporters and is
also shown to be important for the homodimerization of yeast mitochondrial ABC
transporter, Atm1p. We have shown that the Walker A mutant lacks ATP-dependent
heme transport activity and that the lysine mutation does not affect the homodimerization
of ABCB6. In this study, we show that the substrate binding, assessed by using hemin
conjugated to agarose beads, is affected in the Walker A mutant only modestly. However,
the affinity for ATP was drastically reduced. We determined the effect of ATP and
AMPPNP binding to ABCB6-hemin-agarose complex and provided insights into the role
of nucleotide binding in conformational changes in MSDs.
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3.2. Experimental Procedures
3.2.1. Cell Culture and Transfection
NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 4500 mg/L glucose supplemented with 10% FCS, 2 mM L-glutamine, and
antibiotics (Gibco). Cells were plated on 6 well-clustered dish at 3 x 105 cells/well 24
hours prior to transfection and were transfected using LipofectAMINE Plus (Invitrogen)
according to the manufacturer’s protocols.
3.2.2. Site-Directed Mutagenesis
pcDNA3.1-hABCB6-V5-His plasmid was designed to express human ABCB6
with a C-terminal Flag tag. A point mutation was introduced to substitute the lysine
residue at 629 in Walker A motif with a glycine residue using a Quikchange site-directed
mutagenesis kit (Stratagene) and primers (K629G sense; 5’- GTGGGCCCATCTGGGGCAGGGGGGAGCACAATTTTGCGCCTGCTG-3’, K629G antisense; 5’- CAGCAGGCGCAAAATTGTGCTCCCCCCTGCCCCAGATGGGCCCAC-3’). All genes were
thoroughly sequenced after mutagenesis.
3.2.3. Immunoblotting
NIH3T3 cells were transiently transfected with expression plasmids indicated in
the legends. Twenty-four hours after transfection, cells were washed with phosphate
buffered-saline (PBS), scraped into ice-cold PBS containing protease inhibitor cocktail
(complete EDTA free, Roche), and resuspended in buffer A (50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 10% glycerol, and 1 x protease inhibitor cocktail). The samples were then
sonicated and the final concentration of 1% Nonidet P40 added and solubilized by
constant rocking for 1 hr. The samples were centrifuged at 16,000 x g for 15 min at 4˚C
to remove cell debris. The protein concentration was quantified by Bradford method
(Protein assay, Bio-Rad) and lysate was further subjected to immunoblotting or pulldown assays. For immunoblotting, samples were subjected to 10% Laemmli SDS-PAGE
and transferred to a nitrocellulose membrane (Amersham Pharmacia). The blot was
blocked for 2 hr with blocking buffer (10% skim milk in PBS containing 0.1% Tween 20,
PBS-T), incubated with anti-V5 polyclonal (MBL, Japan) antibody for 2 hr, and washed
four times with PBS-T. Subsequently, the blot was incubated with anti-rabbit or mouse
IgG conjugated to horse radish peroxidase (Amersham Pharmacia) for 1 hr, followed by
washing with PBS-T for four times. The bands were detected using enhanced
chemiluminescence detection kits (ECL, Amersham Pharmacia).
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3.2.4. Hemin-Agarose or ATP-Agarose Pull-Down Assays
Cell lysates prepared from cells transfected with ABCB6-V5 or ABCB6-K629GV5 expression plasmids were incubated with hemin conjugated to agarose beads (Sigma)
or ATP-agarose (N6, Sigma) for 30 min or indicated times at 24˚C. The samples were
washed with wash buffer and analyzed by immunoblotting using anti-V5 polyclonal
antibody. The intensity of the bands was analyzed by densitometry using Image J
(http://rsb.info.nih.gov/ij).
3.2.5. Nucleotide-Induced ABCB6 Dissociation
Cell lysates were incubated with hemin-agarose for 30 min at 24˚C to form
ABCB6-hemin-agarose complex. The resin was washed once and resuspended in 200 µl
buffer A. The indicated amounts of ATP or AMPPNP were added to the samples. After
30 min incubation at 24˚C, the amounts of ABCB6 protein remained bound to the resin
were analyzed by immunoblotting and densitometry.
3.3. Results
3.3.1. ABCB6 and ABCB6K629G Display Similar Kinetics for Hemin Binding
Transport activity/mechanism of ABC transporters has been studied rigorously
using mutant forms of proteins in which critical residues involved in the ATP binding
and/or ATP hydrolysis have been substituted with other amino acids, which result in a
loss of function [213, 222]. We have previously generated an ABCB6 mutant construct in
which the conserved lysine residue in the Walker A motif is substituted with a glycine
residue (ABCB6K629G) (Fig. 2.2.). In accordance with previous reports on the other ABC
transporters, ABCB6K629G mutant protein lacks heme transport activity and cells
expressing ABCB6K629G do not accumulate PPIX, an indicator of functional ABCB6
[204]. Moreover, the mutant ABCB6 homodimerizes. To determine the substrate binding
to ABCB6K629G mutant, hemin-agarose pull-down assays were perfomed. Lysates from
NIH3T3 cells transiently transfected with ABCB6-V5 or ABCB6K629G -V5 were
incubated with hemin conjugated to agarose beads, and proteins bound to the heminagarose were analyzed by immunoblotting (Fig. 2.5.). ABCB6K629G -V5 mutant
effectively interacted with hemin-agarose at equilibrium, suggesting that the
conformation of substrate (hemin) binding site is not altered grossly by a mutation in the
NBD. Binding of ABCB6 to hemin-agarose is specific as pre-incubation of lysates with
hemin (80 µM) can compete for the binding and a deletion mutant of ABCB6 does not
bind to hemin-agarose [204].
To further characterize the binding of hemin-agarose to ABCB6 and ABCB6K629G
at equilibrium, different amounts of hemin-agarose were incubated with lysates for the
pull-down assays, and intensity of the bands from immunoblots was quantified by
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densitometry and plotted as a function of hemin-agarose concentration. The binding of
ABCB6 or ABCB6K629G to hemin-agarose was dependent on the amount of heminagarose added as shown in Fig. 3.1.A.
Binding of hemin to ABCB6K629G-V5 was further characterized by determining
the association kinetics. Hemin-agarose pull-down assays were performed at different
time points, and intensity of the bands from Western blot was quantified by densitometry
and plotted as a function of time (Fig. 3.1.B). Non-linear regression equation was used to
perform the curve fitting. There was no significant difference between ABCB6-V5 and
ABCB6K629G-V5 on forming a complex with hemin-agarose.
3.3.2. Loss of the Walker A Lysine Results in Reduced ATP Binding
The substitution of conserved lysine residue in the Walker A motif of ABCB6 did
not affect the dimerization and modestly reduced the rate of ABCB6 association with
hemin. Therefore, the loss of function observed with ABCB6K629G is due either to
changes in the levels of ATP binding or ATP hydrolysis, both of which are critical to
transport activity. To determine the ATP binding of ABCB6 and ABCB6K629G, an ATPagarose pull-down assay was performed at 24˚C. ABCB6-V5 bound to ATP-garose in a
concentration dependent manner, whereas the majority of ABCB6K629G-V5 was
recovered in the flow through even at the highest concentration of ATP-agarose used
(Fig. 3.2.A).
In order to identify whether the loss of affinity for ATP observed with the mutant
protein was unique to lysine to glycine substitution, the homology modeling of NBD
from ABCB6 with several substitutions was performed by Jufang Shan using Hlyb, αhemolysin translocation ATP-binding protein, bound to ATP as a template (Fig. 3.2.B,
only the NBDs with K, K to G, and K to M are shown). In both the mutants, the favorable
interaction between the phosphate group from ATP and the side chain of the lysine is
lost. When free energy for ATP binding was calculated for each mutants (G, M, A, S, T,
and Q), all the mutants had a positive ∆∆G value compared to the wild type (K)
suggesting that the ATP binding is unfavorable for these mutants. However, when
ABCB6K629G-V5 is incubated with ATP-agarose at 37˚C, small amount of ABCB6K629GV5 binds to the beads (Fig. 3.2.C). Therefore, the loss of function seen with
ABCB6K629G-V5 can be attributed to its significantly reduced affinity for ATP. In
accordance with the calculated ∆∆G values for ATP binding of the other mutant NBDs,
substitution of the conserved lysine residue to M, A, S, T, and Q also resulted in a
reduced affinity for ATP (Fig. 3.2.D).
3.3.3. ATP Binding to ABCB6 Changes Its Affinity for Hemin-Agarose
According to the ATP-swith model, release of a substrate from ABC transporters
requires a conformational change from a high affinity substrate binding state to a low
affinity state [114]. If ATP binding is sufficient to induce this conformational change in
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Figure 3.1. ABCB6 and ABCB6K629G binds to hemin-agarose with similar kinetics.
A) ABCB6 and ABCB6K629G show similar Bmax and kd obs. Cell lysates prepared from
NIH 3T3 cells transiently transfected with a plasmid encoding ABCB6-V5 or
ABCB6K629G were incubated with varying amounts of hemin-agarose beads at 24˚C.
Hemin-agarose beads were washed twice, and the samples were analyzed by
immunoblotting. B) The association kinetics is similar for the wild type and mutant
ABCB6. Cell lysates were incubated with hemin-agarose for indicated times at24˚C. The
values are measurement ± S.D.
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Figure 3.2. ATP-binding is severely impaired in Walker A mutant ABCB6.
A) Cell lysates were prepared from NIH 3T3 cells transiently transfected with a plasmid
encoding ABCB6-V5 or ABCB6K629G and incubated with varying amounts of ATPagarose beads (conjugated at N-6) at 24˚C. ATP-agarose beads were washed twice, and
the samples were analyzed by immunoblotting. Flow through from the pull-down assays
was TCA precipitated and also analyzed. B) NBDs from ABCB6, K629G, and K629M
based on homology modeling show a loss of favorable interaction between the phosphate
group of ATP and the side chain from lysine residue. C) Low levels of ABCB6K629G bind
to ATP-agarose at 37˚C. Cell lysates were prepared as described above and incubated
with ATP-agarose at 37˚C. D) Substitution of lysine residue disrupts ATP binding in
ABCB6. Various mutants were tested for ATP binding.
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Figure 3.2. (continued).
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ABCB6, it should dissociate from hemin-agarose upon binding to ATP. On the other
hand, if the ATP hydrolysis is required for the conformational change, then the
incubation with a non-hydrolyzable ATP analog, AMPPNP, will not release ABCB6
from hemin-agarose. Cell lysate was incubated with hemin-agarose and the resultant
complex was purified. Various amounts of ATP were added to the ABCB6-heminagarose complex at 24˚C and the amount of ABCB6 that remained bound to heminagarose was determined by immunoblotting (Fig. 3.3.A). Forty-percent of ABCB6
dissociated from hemin-agarose in the presence of 50 µM ATP, whereas ABCB6K629G,
which has much lower affinity for ATP, shows no decrease in hemin-agarose binding. At
lower ATP concentrations, ABCB6K629G shows a slight increase in hemin-binding, which
is not observed with ABCB6 wild type, for unknown reasons. Nevertheless, ABCB6K629G
dissociation from hemin-agarose is minimal even at the highest ATP concentration tested
(0.5 mM, <20%) in contrast to the wild type ABCB6, in which more than 60% of
ABCB6 dissociated from the beads.
At 24˚C, the rate of ATP hydrolysis is not at its maximum, but to exclude the
possibility of ATP hydrolysis playing a role in the dissociation of ABCB6 from heminagarose, AMPPNP, a non-hydrolyzable ATP analog, was used (Fig. 3.3.B, C). Upon the
addition of AMPPNP to ABCB6-hemin-agarose complex, the ABCB6 dissociated from
hemin-agarose, whereas it had an opposite effect on ABCB6K629G. Compared to ATP,
higher concentration of AMPPNP was required to induce dissociation of ABCB6 from
hemin-agarose. However, it is in good agreement with previous studies that showed 4
mM AMPPNP was required for binding to MRP1 [227].
3.4. Discussion
The nucleotide binding to ABCB6 prompted release of ABCB6 from heminagarose. The change of a high affinity state to a low affinity state for hemin-agarose does
not require ATP hydrolysis because a non-hydrolyzable ATP analog, AMPPNP,
effectively disrupts the interaction between ABCB6 and hemin-agarose. Our results here
are consistent with a substrate transport model where the formation of NBD dimer upon
substrate and nucleotide binding provide the power stroke for transport. Moreover, unlike
another mitochondrial half transporter, Atm1p, a mutation in the conserved lysine in the
Walker A domain did not affect homodimerization of ABCB6. The mutation, however,
drastically impaired the ATP binding to ABCB6. Therefore, nucleotides did not have
effects on the Walker A mutant ABCB6 bound to hemin-agarose.
The mutation of the conserved lysine residue in Walker A motif has different
effects depending on ABC transporters [213]. This can be partly attributed to the
asymmetrical NBDs in many full transporters and the heterodimeric half transporters,
where one site shows a low affinity for ATP or low ATPase activity. In the asymmetrical
NBDs, one ATPase site contains the consensus sequence whereas the other site contains a
degenerate sequence [111]. Therefore, the mutation in the degenerate site may not result
in a lack of transport activity, because the consensus site provides all the functionalities
(e.g., ATP binding and hydrolysis). Because the Walker A mutant ABCB6
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Figure 3.3. Binding of nucleotides to ABCB6 changes affinity for hemin-agarose.
A) A schematic drawing of roles ATP binding and ATP hydrolysis can play in substrate
transport cycle. B) ATP induces a conformational change from a high affinity substrate
binding to a low affinity binding state. C) AMPPNP induces a dissociation of ABCB6
from hemin-agarose.
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homodimerizes, both ATPase sites contain mutated Walker motif and, therefore, ATP
binding is severely impaired. Whether ABCB6 is normally bound to ATP or ADP under
physiological conditions, which was suggested for TAP1/TAP2 heterodimer [111], still
needs to be determined. In TAP1/TAP2, substrate binding promotes ATP exchange at the
NBD, which results in the formation of NBD dimer. The substrate binding is unlikely to
be affected by the presence of ATP because ATP depletion does not affect peptide
binding to TAP1/TAP2 [228]. In addition, inability to bind ATP did not affect the Walker
A mutant ABCB6 binding to hemin-agarose. In either case, ATP binding affects the
dimer formation of NBD [110, 111, 224]. Purified TAP1/TAP2 NBDs do not
heterodimerize, suggesting that the formation of dimer is not an intrinsic feature [111].
The equilibrium binding to hemin-agarose saturated at 1 mM and a slight decrease
in the binding was observed when higher concentrations of hemin-agarose (>3 mM) were
added. The concentration of hemin-agarose needed to reach the saturation was relatively
high. However, we have previously shown that 40 µM hemin displaces >90% of ABCB6
bound to hemin-agarose [204] suggesting that the Kd observed using hemin-agarose is
likely to be much higher than the actual Kd for free hemin. The agarose beads may be a
limiting factor for the amount of ABCB6 molecule to bind to hemin-agarose requiring
apparently much higher concentration to reach a saturation point.
Even though functions of NBD and MSD are tightly coupled, how the changes in
NBD are transmitted to MSD and vice versa has not been shown clearly because the
structural data of a mammalian ABC transporter are lacking. Structural data on the
soluble NBDs provided an insight into how ATPase sites are formed between two NBDs
and the conformational changes that they undergo when bound to nucleotides [110, 111].
The structure of a sandwich NBD dimer and other biochemical data led to a substrate
transport model that ATP binding induces a conformational change sufficient to release
substrates [114]. The structure of nucleotide-bound bacterial ABC transporter Sav1866,
which shows a significant sequence similarity to human ABCB subfamily members,
shows an outward opening of TM helices [97]. The NBD is in a closed dimer and the
cavity in the membrane created by TM helices is not accessible from the cytosol.
Therefore, the cavity is suggested to represent the substrate translocation path into the
extracellular space. The outward facing cavity of ATP-bound MDR1 has also been
shown using electron microscopy [229, 230]. Binding of AMPPNP to ABCB6 results in a
release of ABCB6 from hemin-agarose suggesting that ABCB6 undergoes
conformational changes between a high affinity to a low affinity state for substrates
depending on nucleotide binding status. A higher concentration of AMPPNP was
required to release 50% of ABCB6 from hemin-agarose compared to ATP. However, the
concentration used in this study (5 mM) to observe an effect is consistent with previous
studies that showed 4 mM AMPPNP was required to bind to MRP1 NBD1 [227]. The
condition this experiment was performed, room temperature, is not ideal for ATP
hydrolysis and, therefore, the effect of ATP hydrolysis on the conformational changes
should be minimal. Taken together, our results provide biochemical evidence that a
substrate is released from ABC transporter upon nucleotide binding and support the ATP
switch model.
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CHAPTER 4. ABCB6 CONTAINS AN N-TERMINAL ER EXIT SIGNAL THAT
IS CONSERVED IN OTHER ABC TRANSPORTERS
4.1. Introduction
ATP-binding cassette (ABC) transporters are involved in the ATP-dependent
transmembrane movement of various compounds [2]. Their diverse physiological
functions have been revealed because ABC transporter deficiencies lead to human
diseases such as cystic fibrosis, Dubin-Johnson syndrome, X-linked sideroblastic anemia
and ataxia and hyperinsulinemic hypoglycemia [2]. ABC transporters at the plasma
membrane extrude endogenous compounds, but also protect cells by reducing the
accumulation of toxic compounds. Moreover, ABC transporters are found in subcellular
organelles and play key roles in biological processes such as heme biosynthesis, [Fe-S]
cluster formation, and antigen presentation.
ABC transporter localization specifically to the plasma membrane or to
subcellular organelles suggests inherent signals within the transporter are required to
ensure proper localization. However, among ABC transporters, it is difficult to identify a
typical sequence or modification that affects all membrane transporters. For example,
lack of ABCG8 glycosylation causes ER retention, and apical localization of ABCB11
requires at least two out of the four N-glycosylation sites [133, 231]. In contrast,
CFTR/ABCC7 membrane localization is independent of N-glyosylation [232].
In the ER, several covalent post-translational modifications occur, which include
signal sequence cleavage, N-glycosylation, and disulfide bond formation. Disulfide bonds
are formed in the ER via the action of protein disulfide isomerase enzymes. If essential
disulfide bond(s) are not formed, some proteins are retained in the ER [233] by a process
referred to as “thiol retention” [234]. Thiol retention has been shown to regulate the ER
exit of adiponectin [235] and IgM. If the free thiols in IgM are not oxidized by formation
of disulfide bonds or by other means, then IgM does exit the ER [236, 237]. IgM egress
from the ER can be manipulated by changing the cellular redox environment with thiol
reductants (e.g. DTT or β-ME) [238].
We have previously shown that ABCB6 is a homodimeric porphyrin transporter,
which through its localization at the mitochondrial outer membrane facilitates heme
biosynthesis [204]. ABCB6’s high expression in human and murine fetal liver coincides
with definitive erythropoiesis. As expected, ABCB6 is upregulated during differentiation
of progenitor cells toward the erythroid lineage. This is consistent with the requirement
for porphyrins in erythropoiesis as erythroid cells require a high heme production to
ensure hemoglobin synthesis [176]. Furthermore, ABCB6 function is necessary to ensure
efficient heme biosynthesis. Heme biosynthesis occurs in two compartments, and the
energetic constraints of shuttling the anionic heme precursor, CPgenIII from the cytosol
into the intermembrane space where the next enzyme in the pathway resides, make this a
potential rate-limiting step that ABCB6 can overcome by transporting CPgenIII across
the outer membrane [176].
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While ABCB6 is a mitochondrial outer membrane protein, it is not clear how
ABCB6 trafficks in the cells, what signals are required for the trafficking, or if these
signals are required for function. In this study, we show that ABCB6 is modified by
glycan addition at only one site. Moreover, ABCB6 trafficks through the ER to the Golgi,
a process that requires the formation of a disulfide bond between two cysteines present at
the N-terminus. Notably the ABCC subfamily members that insert their N-terminal into
the ER lumen (e.g. ABCC1, C2, etc.) contain N-terminal cysteines that may form a
disulfide bond. The functional significance of these cysteines were revealed in
SUR1/ABCC8, a plasma membrane K+ channel regulator [83]. We discovered a single
mutation in this conserved cysteine in SUR1/ABCC8 from a patient with defective K+
channel function. As a consequence of this single point mutation in the conserved
cysteines, SUR1/ABCC8 was incapable of trafficking to the plasma membrane. Our
findings have uncovered a conserved N-terminal disulfide bond, which provides an
important signal for ER exit of ABC transporters and suggests that alterations in the
redox status of the ER can impact ABC transporter trafficking.
4.2. Experimental Procedures
4.2.1. Cell Culture
NIH3T3 cells, Mel cells and K562 vector or ABCB6-Flag cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 4500 mg/L glucose
supplemented with 10% FCS (HyClone, Logan, UT), 2 mM L-glutamine, 100 units/ml
penicillin, and 100 ug/ml streptomycin (Gibco, Carlsbad, CA) in humidified atmosphere
containing 5% CO2 at 37 ˚C. NIH3T3 cells were seeded on 6 well-clustered dishes (3 x
105 cells/well) 24 hours prior to transfection, and then transiently transfected with
expression plasmids (total of 1µg except for when otherwise indicated) using
LipofectAMINE Plus (Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocols.
4.2.2. Site-Directed Mutagenesis
Plasmids pcDNA3-hABCB6-Flag and pcDNA3.1-hABCB6-V5-His were
designed to express human ABCB6 with a C-terminal tag, Flag or V5 respectively as
previously described [204]. A point mutation was introduced into pcDNA3.1-hABCB6V5-His using a Quikchange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and
primers (N447Q, sense, 5’-CGTGCTATGAACACACAGGAGCAAGCTACCCGGGCACGAGCAGTG-3’, antisense, 5’- CACTGCTCGTGCCCGGGTAGCTTGCTCCTGTGTGTTCATAGCACG-3’; N498Q, sense, 5’-GCGCTTCACTGGTTTTACTACAACAGACCCAGAACCTGGTGATTG3’, antisense, 5’-CAATCACCAGGTTCTGGGTCTGTTGTAGTAAAACCAGTGAAGCGC-3’; N677Q, sense, 5’-CCCAAGACACTGTCCTCTTTCAAGACACCATCGCCGACAATATC-3’, antisense, 5’-GATATTGTCGGCGATGGTGTCTTGAAAGAGGACAGTGTCTTGGG-3’; N775Q, sense, 5’-TCTGGCCAA-
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AGTCTGTGCCCAACGCACCACCATCGTAGTGGC-3’, antisense, 5’-GCCACTACGATGGTGGTGCGTTGGGCACAGACTTTGGCCAGAG-3’; N6Q, sense, 5’-CTTGCCATGGTGACTGTGGGCCAATACTGCGAGGCCGAAGGGCC-3’, antisense, 5’-GGCCCTTCGGCCTCGCAGTATTGGCCCACAGTCACCATGGCAAG-3’; C8S, sense, 5’GGTGACTGTGGGCAACTACTCCGAGGCCGAAGGGCCCGTGG-3’, antisense, 5’CCAC-GGGCCCTTCGGCCTCGGAGTAGTTGCCCACAGTCACC-3’; C26A, sense,
5’-GCAGGATGGCCTGAGTCCCGCCTTCTTCTTCACGCTCGTGCC-3’, antisense,
5’-GGCACGAGCGTGAAGAAGAAGGCGGGACTCAGGCCATCCTG-C-3’; C50A,
sense, 5’-GCCTTGGTGCTGGCTCTTCCCGCTAGACGCCGGGAGCGG-CCCGC-3’,
antisense, 5’-GCGGGCCGCTCCCGGCGTCTAGCGGGAAGAGCCAGCACCAAGGC-3’; C120A, sense, 5’-CTGGAGAGTCTGGCCGGCGCCGCTGGCCTGTGGCTGCTTGTCGTG-3’, antisense, 5’-CACGACAAGCAGCCACAGGCCAGCGGCGCCGGCCAGACTCTCC-AG-3’). All genes were thoroughly sequenced after mutagenesis. A point
mutation was introduced into pcDNA3.1-hABCB6-N447Q-V5-His at N498 as described
above to yield pcDNA3.1-hABCB6-N447,498Q-V5-His. The pcDNA3.1-hABCB6-Q4V5-His mutant was generated by introducing a point mutation into pcDNA3.1-hABCB6N447, 498Q-V5-His at N677 and then at N775. An additional mutation was introduced
into pcDNA3.1-hABCB6-Q4-V5-His at N6 to generate pcDNA3.1-hABCB6-Q5-V5-His.
pcDNA3.1-hABCB6-C8S,C26A-V5-His was generated by introducing a point mutation
into pcDNA3.1-hABCB6-C8S-V5-His at C26.
To generate truncated mutant constructs to determine the disulfide bond
formation, point mutations were introduced into constructs pcDNA3.1-hABCB6-V5 at
C50 and then at C120 using primers described above. And then the N-terminus of the
mutant ABCB6 construct containing amino acids 1 to 210 with Flag tag at the C-terminus
was amplified using primers (sense, 5’-GCCATGGTGACTGTGGGCAACTACTGCGAGGCCG-3’, and antisense, 5’-CCTACTTATCGTCGTCATCCTTGTAATCACGAAGTCCAGGGGCCCAGAG-3’) with the following condition (94˚C, 4 min, denaturing at
94˚C for 30 sec, annealing at 56˚C for 30 sec, and reaction at 68˚C for 1 min for 30
cycles). The PCR product was purified from agarose gel and TA-cloned into pCR2.1TOPO vector (Invitrogen). The inserts were sublconed into pcDNA3 using HindIII/XbaI
sites to obtain pcDNA3-hABCB6-C50/120A-N1-210-Flag.
4.2.3. Immunoblotting
Twenty-four hours after transfection, cells were washed with PBS and then
scraped into 1 ml cold PBS containing 1 x commercial protease inhibitor cocktail
(complete EDTA free, Roche, Mannheim, Germany). Cells were pelleted by
centrifugation at 1,000 x g for 4 min at 4˚C, and were resuspended in buffer A (50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, and 1 x commercial protease inhibitor
cocktail (complete, Roche)), and sonicated (three 10 sec pulses). Nonidet P40 (NP-40,
final concentration of 1%) was added to solubilize the cells, followed by constant rocking
for 60 min at 4˚C. Samples were then centrifuged at 17,000 x g for 15 min at 4˚C to
remove cell debris. Protein concentration in the supernatant was measured by Bradford
method (Protein Assay, Bio-Rad Laboratories Inc., Hercules, CA). The lysate was further
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processed for either immunoblotting or glycosidase digestion. For immunoblotting,
Laemmli sample buffer containing β-ME unless otherwise indicated (final concentration
1x, Bio-Rad Laboratories Inc.) was added to the supernatant and the samples were
fractionated on 7.5, 10 or 12.5% SDS-PAGE. Afterward, proteins were transferred to a
nitrocellulose membrane (Amersham Biosiences). The blots were blocked with 10% skim
milk in PBS-T and incubated with either anti-FLAG (M2 or polyclonal, Sigma), anti-V5
polyclonal (MBL, Nagoya, Japan), anti-ABCB6 (serum), or anti-ABCB6 monolconal
antibodies. The blots were washed with PBS-T, incubated with secondary antibodies
(horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG F(ab’) fragment,
Amersham Pharmacia Biotech., Liscataway, NJ), and immunoreactive proteins detected
by using enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech.).
4.2.4. Glycosidase Digestion
Lysates were prepared as described above from NIH3T3, K562, or Mel cells.
After denaturation in 1 x denaturing buffer (0.5% SDS, 1% β-marcaptoehtanol), the
samples were incubated at 37˚C for 1 hr with or without PNGase F (New England
Biolabs, Inc., Beverly, MA) in reaction buffer (50 mM Na2PO4 (pH 7.5) and 1% NP-40)
according to the manufacturer’s recommended procedures. For EndoH digestion, the
denatured samples were incubated with or without the enzyme in 50 mM sodium citrate
buffer.
4.2.5. Mitochondria Isolation
K562 or Mel cells were pelleted, washed with PBS, and resuspended in
resuspension buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 7.6), and 1 x
protease inhibitor cocktail (Roche). After 10 min incubation on ice to allow the cells to
swell, they were broken with type B Dounce homogenizer. 2.5 x membrane stabilizing
buffer (525 mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl (pH 7.6), and 2.5 mM
EDTA) was added to the homogenate to a final concentration of 1 x. The samples were
centrifuged at 1,300 x g for 5 min at 4 ˚C to remove cell debris and nuclei. The
supernatant was further centrifuged at 17,000 x g for 15 min at 4˚C to pellet
mitochondria.
4.2.6. Pulse Chase
K562 vector or ABCB6-Flag cells (~ 2 x 106 cells) were washed with warm 1 x
Hank’s buffer and incubated in labeling media (DMEM without L-methionine, L-cysteine
(Cellgro, Manassas, VA), 10% dialyzed FBS (Hyclone), 2 mM L-glutamine) containing
0.1 mCi/ml [35S] (Trans 35S-label,[35S] L-Methionine, [35S] L-Cysteine, 1175
Ci/mmol, MP Biomedicals, Inc. Irvine, CA) for 20 min at 37˚C. Cells were then washed
once with chase media (complete DMEM supplemented with 2 mM L-methionine and Lcysteine) and chased for times indicated in the figures. At the end of each chase time
interval, cells were washed with cold PBS, pelleted, flash frozen in liquid N2 and stored
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at -80˚C until use. Cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl (pH 7.5), 150
mM NaCl, 0.5% deoxycholate, and 0.5% NP-40) for 15 min on ice and cell debris was
removed by centrifugation at 15,000 x g for 10 min at 4˚C. The lysate was incubated with
20 µl anti-Flag M2 antibody conjugated agarose (50% slurry, Sigma) for 2 hr at 4˚C with
constant rotation. The beads were washed three times with Washing buffer (50 mM TrisHCl (pH 7.5), 400 mM NaCl, 0.5% deoxycholate, 0.5% NP-40) and then resuspended in
2 x Laemmli SDS sample buffer containing β-ME. Samples were separated by SDSPAGE. The gel was fixed, stained by Coomassie G-250 (GelCode Blue, Pierce),
incubated with Amplify fluorographic reagent (Amersham, GE Healthcare) and was
dried. [35S]-labeled proteins were detected by autoradiography.
4.2.7. Glycosylation Site Prediction
To search for potential N-glycosylation site(s) in ABCB6 sequence, PROSITE
motif search, which scans for a consensus motif N-X-S/T-X where X can be any amino
acid except for proline, was performed (http://www.predictprotein.org, accessed Oct. 13,
2004).
4.2.8. Detection of SUR1
A series of SUR1/ABCC8 mutant constructs were generated where Cys6 and
Cys26 were singly or doubly mutated to alanine or serine. Rest of the 27 cysteine
residues were mutated to either alanine or serine in these constructs. COSm6 cells were
co-transfected with the various SUR1 constructs with KIR6.2. SUR1 was affinity labeled
with [125I]-azidoglibenclamide, fractionated on SDS-PAGE, and detected by
autoradiography.
4.3. Results
4.3.1. Both Endogenous and Exogenous ABCB6 Are Glycosylated
Glycosylated proteins, which are synthesized in the ER, are often observed as
broad or smeared bands on immunoblotting. Although ABCB6 is a mitochondrial
protein, which are typically not glycosylated, we tested if it was modified by N-linked
glycans because ABCB6 appeared as a broad band on immunoblots. Crude mitochondrial
preparations from either human erythroleukemia K562 or murine erythroleukemia Mel
cells were treated with either PNGase F to remove high mannose and complex glycans
from asparagine residues or Endo H, which only reacts with high mannose glycans found
on proteins as long as they remain in the ER. Immunoblot analysis (using both an antiABCB6 antiserum and a monoclonal antibody we developed to a conserved epitope)
revealed faster migration of both human and murine ABCB6 after PNGase F but not
Endo H treatment (Fig. 4.1.). The PNGase F sensitivity and Endo H resistance
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Figure 4.1. ABCB6 is glycosylated.
Crude mitochodria preparations from A) K562, human erythroleukemia or B) Mel,
murine erythroleukemia cells were treated with PNGase F or Endo H and ABCB6 was
detected by immunoblotting. Cell lysates from C) K562 cells expressing vector or
ABCB6-Flag or D) NIH3T3 cells transiently transfected with ABCB6-V5 were treated
with PNGase F and analyzed by immunoblotting. E) ABCB6 was no longer glycosylated
when K562 cells expressing ABCB6-V5 were treated with tunicamycin. F) Pulse chase
assay using K562 cells expressing ABCB6-Flag showed the glycosylated ABCB6 at 60
min.
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Figure 4.1. (continued).
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demonstrate that both human and murine ABCB6 are glycosylated and traffick through
the ER to the Golgi.
We next tested whether epitope-tagged human ABCB6 exhibited the same pattern
of glycosidase sensitivity. We found that the ABCB6, transfected into K562 and NIH3T3
cells, was PNGase F sensitive (Fig. 4.1.). These results demonstrate that epitope-tagged
ABCB6 trafficks like endogenous ABCB6. Moreover, this processing pathway is
indistinguishable between erythroid and non-erythroid cells. The extent of glycosylation
does differ between species with ABCB6 in human cells showing multiple bands whereas
ABCB6 in mouse cells shows only one discrete band. To understand the pathway leading
to ABCB6 glycosylation, we used two experimental approaches: pulse chase labelling
and treatment with tunicamycin (TNM), an inhibitor of glycan synthesis in the ER.
Treatment of K562 cells stably expressing ABCB6-V5 with TNM abolished the high
molecular weight bands (Fig. 4.1.). Tunicamycin sensitivity of ABCB6 glycan
modification confirms that ABCB6 trafficks through the ER. We performed a pulse chase
experiment to follow the maturation of ABCB6. The CHO-TRex system was used
previously to transiently express ABCB6 in order to demonstrate ABCB6-activated de
novo porphyrin biosynthesis [204]. Therefore, given that the exogenous ABCB6 activates
heme biosyntheis like the endogenous protein, exogenous ABCB6 was likely to proceed
via a processing pathway similar to the endogenous one in this system. CHO cells
harboring the reverse tet operator were transfected with pcDNA4-ABCB6-Flag, treated
with tetracycline, and then pulsed for 20 min with [35S]-Cys/Met labeling mixture in
media lacking Cys/Met. Cells were collected after various chase intervals, and
immunoprecipitated [35S]-labeled ABCB6 was separated by SDS-PAGE and detected by
autoradiography. Slower migrating forms of ABCB6 were detected at 60 and 120 min
after the pulse, which are likely to correspond to further modification of the N-linked
glycans in the Golgi (Fig. 4.1.).
4.3.2. ABCB6 Is Glycosylated at an Atypical N-X-C Site
Potential N-glycosylation site(s) in ABCB6 sequence were identified using
PROSITE motif search (http://www.predictprotein.org, [239]), which scans a consensus
glycosylation motif N-X-S/T-X (X can be any amino acid except for proline [240]). The
search results revealed four potential glycosylation sites in human ABCB6, which are
also conserved in mouse Abcb6 (Fig. 4.2.A). We have previously shown that the Cterminus of ABCB6 (containing the nucleotide binding domain) resides in the cytoplasm
[204]; therefore, Asn677 and Asn775 are unlikely targets for glycosylation because they
will not face the site of glycosylation in the ER lumen. Nevertheless, each asparagine (N)
residue was individually substituted with glutamine (Q) to develop four ABCB6 mutant
constructs. Further, a double asparagine mutant where both Asn447 and Asn498 were
substituted with glutamine residues was generated in the event more than one
glycosylation site is used. All five ABCB6 asparagine mutants contained a V5 epitope tag
at the C-terminus and were transiently expressed in NIH3T3 cells. The migration patterns
of ABCB6 asparagine mutants were assessed after PNGase F treatment (Fig. 4.2.B).
Unexpectedly, individual or double ABCB6 asparagine mutants showed the same
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Figure 4.2. ABCB6 is glycosylated only at the atypical N-X-C site.
A) Four consensus and one atypical glycosylation sites in human ABCB6. B, C)
Asparagine residues in the consensus or the atypical (N6Q) sites were substituted with
glutamine residues. NIH3T3 cells were transiently transfected with B) single mutants and
C) Q4 mutant in which all four Asn residues were mutated, or D) single mutant N6Q or
Q5 in which all five Asn residues were mutated with glutamine. Proteins were subjected
to glycosidase treatment and analyzed by immunoblotting using anti-V5 antibody. The
presence of glycans was determined by the mobility shift in the immunoblotting.
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Figure 4.2. (continued)
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migration pattern as the wild-type protein, in that they migrated faster after treatment
with PNGase F, which indicates these asparagine mutations do not change ABCB6
glycosylation. Therefore, to rule out the possibility of multi-site glycosylation, all four
asparagine residues in the consensus glycosylation motifs were substituted with
glutamine residues (designated as Q4 mutant). Surprisingly, Q4 behavior was identical to
the wild-type protein such that the faster migrating band (immature ABCB6) was only
seen when treated with PNGase F (Fig. 4.2.). These results indicate that other
glycosylation site(s) must exist.
An extensive review of the available literature revealed five proteins that use a
cysteine residue instead of the typical serine or threonine at the glycosylation site (N-XC) [241-245]. These proteins are typically secreted proteins. However, because these
proteins have other typical glycosylation sites and the N-X-C motif represents a minority
of the glycosylation sites, its functional significance remains unknown. The five proteins
are: Protein C (1/4), von Willebrand factor (1/12), fetal antigen I (2/3), transferrin (1/3),
and CD69 (1/2), and the proportion of N-X-C motifs out of the total number of
glycosylation sites is indicated in the parentheses. Examination of the ABCB6 sequence
revealed one atypical glycosylation motif near the N-terminus, N-Y-C starting at position
6 (Fig. 4.2.). To test the possibility that this site was used in ABCB6, the asparagine
residue at position 6 was substituted with a glutamine residue in both wild-type and Q4
constructs to generate N6Q and Q5 ABCB6 constructs respectively. The ABCB6
asparagine mutants were transiently transfected into NIH3T3 cells, treated with PNGase
F and analyzed by immunoblotting using anti-V5 antibody (Fig. 4.2.). Both Q5 and N6Q
migrated faster than the wild-type ABCB6-V5 and their mobility was unaffected by
PNGase F treatment and identical to the PNGase F-treated wild-type protein. These
findings indicate that ABCB6 uses the N-X-C motif as its sole glycosylation site.
Generally, ABC half transporters contain six TM helices; however, the unique
glycosylation site at the N-terminus and the cytoplasmic localization of the C-terminus
allowed us to develop a topological model that contain more than six TM helices for
ABCB6. Accordingly, programs such as TopPred and TMHMM predicted ABCB6 to
contain nine TM helices [218, 219], while HMMTOP and SOSUI predicted 11 and 10,
respectively [220, 246, 247]. TopPred, TMHMM, and HMMTOP predicted that the sole
glycosylation site is protruded into the ER lumen. The absence of glycans at Asn677 and
Asn775 is consistent with the C-terminus in the cytoplasm, which is in agreement with
our previous biochemical findings [204]. These results indicate that N- and C-termini are
on the opposite sides of the membrane and suggest that ABCB6 contains an odd number
of TM helices. The lack of glycosylation at the consensus sites Asn447 and Asn498
suggests that these residues are not accessible to the glucosyltransferase (although not all
N-X-S/T sites are used in secretory proteins), and, therefore, are likely to reside in the
cytoplasm. Only the predictions from HMMTOP and TMHMM satisfy all these criteria,
in which HMMTOP model contains extra two TM helices (248-271A.A. and 392326A.A.) in place of a large cytoplasmic loop in the TMHMM prediction (Fig. 4.3.). It is
notable that we have identified a form of ABCB6 that lacks amino acids 240 to 289,
which we have previously shown is incapable of binding heme.
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Figure 4.3. ABCB6 is predicted to contain 9 TM helices.
Schematic drawing of membrane topology of ABCB6. TM helices in ABCB6 amino acid
sequence (NP 005680.1) were predicted using A) HMMTOP or B) TMHMM. Topology
model representation was generated by TMRPres2D ([248]
http://bioinformatics.biol.uoa.gr/TMRPres2D). The additional luminal loop in HMMTOP
is boxed. C) Glycosylation site insertion shows that TMHMM prediction appears to be
valid. N-glycosylation sites were introduced into N6Q mutant lacking inherent
glycosylation site and the mutants were analyzed for glycosylation status using PNGase
F.
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In order to validate the membrane topology of ABCB6, consensus glycosylation
sites were introduced into the non-glycosylated form of ABCB6, ABCB6-N6Q at
positions V290T and L292N). If HMMTOP prediction is valid, then V290T and L292N
mutants, which contain perfect consensus sites for glycosylation at Asn288 or Asn290 in
the additional luminal loop predicted only in HMMTOP, will be glycosylated. These
ABCB6 constructs along with an unmodified ABCB6 were transiently expressed in
NIH3T3 cells and lysates were treated with PNGase F. The PNGase F sensitivity of each
mutant was analyzed by immunoblotting (Fig. 4.3.). An additional ABCB6 control was
developed in ABCB6-N6Q where Glu236 was substituted with asparagine residue
(Q236N) to make a consensus glycosylation site in the predicted cytoplasmic loop.
Accordingly, this mutant ABCB6 was not glycosylated. Moreover, V290T and L292N
were not glycosylated as only the fast migrating band was observed even in untreated
samples. Because these sites were not accessible to glucosyltransferase, they are likely to
reside in the cytoplasm, favoring the membrane topology predicted by TMHMM.
4.3.3. Cysteine Is Dispensable for Glycosylation but Is Critical for ER Exit
Since ABCB6 is only glycosylated at the atypical glycosylation motif, we next
tested if the cysteine in N-X-C was required for glycosylation of ABCB6. The cysteine
residue was substituted with a serine residue to make a consensus glycosylation site (NX-S, labeled C8S). The C8S mutant was transiently expressed in NIH3T3 cells and
glycosylation state was evaluated by PNGase F treatment. The ABCB6-C8S was PNGase
F sensitive indicating that the cysteine residue is not required for glycosylation (Fig.
4.4.). As a control, we showed that glycine substitution to form a non-consensus site
caused a loss of glycosylation, which underscores the importance of having either the
consensus N-X-S/T or N-X-C motif for glycosylation. Unexpectedly, C8S mutant was
Endo H sensitive indicating that this mutant failed to exit the ER (Fig. 4.4.).
Despite glycosylation, the retention of ABCB6-C8S in the ER suggested this
residue might play a role in ER to Golgi trafficking. We found that Cys8 is highly
conserved among human, chimpanzee, mouse, rat, and zebrafish (Fig.4.5.A ) suggesting a
conserved function of this residue across species. Notably, the asparagine residue for
glycosylation in not conserved in zebrafish. This analysis also revealed a conserved
downstream cysteine residue at position 26. Based on our computer-assisted analysis,
both TMHMM and HMMTOP predict Cys26 would be in the ER lumen. To determine if
Cys26 played a role in ER to Golgi trafficking, we mutated the cysteine residue to alanine
or serine residue in the wild-type and C8S mutant. Single mutants, C26A and C26S, were
both PNGase F and Endo H sensitive like the trafficking-impaired ABCB6-C8S (Fig.
4.5.B). Furthermore, the mutant lacking both cysteine residues, C8S/C26A and C8S/26S,
were Endo H sensitive. These results indicate that both Cys8 and Cys26 are critical for
the ER exit of ABCB6. We hypothesized that we could rescue trafficking defect by
inserting a cysteine residue just downstream from C8S; therefore, a cysteine residue was
inserted between Glu9 and Ala10 to create C8S/C10in mutant. However, this construct
failed to acquire Endo H resistance, which indicates that the space between the two
cysteines is important to ER exit of ABCB6 (Fig. 4.5.C).
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Figure 4.4. Cys8 is dispensable for glycosylation but is critical for ABCB6 ER exit.
A) Cys8 is substituted with serine or glycine and the mutant proteins were transiently
expressed in NIH3T3 cells. The glycan modification of the mutants was determined by
PNGase F sensitivity and analyzed as in Fig. 4.3. ABCB6 is still glycosylated when C8 is
substituted with Ser to make a consensus motif. B) Total lysates from NIH3T3 cells
expressing either wild type ABCB6, C8S, or N6Q mutants were analyzed for PNGase F
and Endo H sensitivity.
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Figure 4.5. Both Cys8 and Cys26 are required for ER exit of ABCB6.
A) Cys8 and Cys26 are highly conserved among species. Amino acid sequence alignment
of ABCB6 from human, mouse, rat, dog, chimpanzee, and zebrafish. Only the Nterminus of each sequence is shown. Dog ABCB6 contains a long additional N-termius
that is omitted from this figure. Red arrowhead indicates the N-glycosylation site,
whereas black arrowheads indicate the conserved cysteine residues. B) Cys26 is
substituted with alanine or serine on wild-type or C8S mutant. The mutants were
analyzed for glycosidase sensitivity as in Fig. 3. Cys26 mutants and double mutants also
failed to exit the ER. C) Cysteine residue was inserted between position 9 and 10 in C8S
mutant to create a possible site for disulfide bond formation with Cys26.
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4.3.4. Cys8 and Cys26 Form Intramolecular Disulfide Bond
Because two conserved cysteine residues facing the ER lumen are critical for the
ER exit of ABCB6, we next tested if they formed an intramolecular disulfide bond.
Intramolecular disulfide bonds are detected by mobility shifts of bands in non-reducing
compared to reducing SDS-PAGE, because the disulfide bonds produce protein
compaction resulting in a faster migration under non-reducing conditions compared to the
reduced ones. The extent of the band shift is positively correlated with the distance
between the two participating cysteine residues. We reasoned that the minimal number of
residues separating the two conserved cysteines in ABCB6 (17 A.A.) would produce a
barely detectable band shift in a protein with a molecular mass of 94 kDa. Therefore, we
developed an ABCB6 chimeric protein that contained 210 amino acids from the Nterminus fused to GFP. The mutant exhibited PNGase F sensitivity and Endo H
resistance, the pattern similar to full length ABCB6 (Fig. 4.6.B). According to the
membrane topology prediction, N1-210 mutant spans the membrane five times and places
the tagged-C-terminus in the cytoplasm (Fig. 4.6.A). To distinguish the band shift better,
the same truncation mutant was tagged with a Flag epitope instead of a bulky GFP
molecule. This construct has a further advantage because the different forms of nonglycan and glycan modified ABCB6 can be identified. In order to eliminate any
contaminating effects from the other cysteine residues in the construct (inter- or
intramolecular disulfide bonds via other cysteines), Cys50 and Cys 120 were substituted
with alanine residues in the mutant construct (ABCB6N1-210-Flag and ABCB6C50/120AN1-210-Flag).
Three distinct bands were readily seen upon analyzing ABCB6C50/120AN1-210Flag by immunoblotting (Fig. 4.6.C). Glycosidase assays allowed us to determine the
identity of each band: the slowest migrating band (a) is PNGase F sensitive and Endo H
resistant band and represents the mature ABCB6 with complex glycans, the middle band
(b) is PNGase F and Endo H sensitive and represents ER-type ABCB6 with high
mannose modification, and the fastest migrating band (c) contains no glycans and is,
therefore, the immature ABCB6. The size of the truncated ABCB6 allows separation of
the very distinct forms of ABCB6 unlike the full-length ABCB6.
We next transfected ABCB6N1-210-Flag and ABCB6-C50/120AN1-210-Flag into
K562 cells and analyzed the proteins in the presence or absence of reducing agent DTT.
Cells were treated with and harvested in the presence of alkylating agent NEM to prevent
spontaneous disulfide bond formation. ABCB6 samples ran in the absence of DTT
migrated faster compared to the reduced samples suggesting that ABCB6 has different
folding under non-reducing conditions due to a disulfide bond (Fig. 4.6.D).
4.3.5. N-terminal Cysteine Residues Are Conserved in the Long MRPs
The “core” unit of ABC transporters consists of a membrane-spanning domain
(MSD) with six TM helices and a nucleotide-binding domain (NBD) [87]. Functional
transporters require two sets of such core units; full transporters contain two units in
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Figure 4.6. N-terminus of ABCB6 contains a disulfide bond.
A) Schematic drawing showing that ABCB6N1-210 mutant spans the membrane five times
based on TMHMM prediction with GFP in the cytoplasm. B) ABCB6N1-210 truncated
mutant is processed similarly to the full-length protein. Typical results from glycosidase
assays are shown. Mouse ABCB6 construct with a C-terminal GFP were used for these
experiments. N1-210 showed very low Endo H sensitivity. C) ABCB6-C50/120AN1-210Flag was analyzed as in Fig. 4.3. Identity of each band is described in the text. D)
ABCB6N1-210-Flag and ABCB6-C50/120AN1-210-Flag were expressed in K562 cells. K562
cells were treated with NEM for 10 min and then the lysates were prepared in the
presence of NEM. Samples were separated on 12.5% SDS-PAGE with or without
reducing agent DTT and analyzed by immunoblotting.
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tandem in a single polypeptide and half transporters with one such unit either need to
homo- or hetero-dimerize. Since most ABC transporters contain an even number of TM
helices (six in one MSD), both N- and C-termini reside in the cytoplasm. Some members
of ABCC subfamily, however, contain additional MSD with 5 TM helices N-terminal to
the MSD1 placing the N-terminus at the luminal or extracellular side [249]. Therefore,
we investigated whether the N-terminal cysteine residues found in ABCB6 were
conserved in some of these long MRPs. The alignment of amino acid sequence from
ABCC1, C2, C3, C6, C8, C9, and B6 using clustal V showed that the two cysteines are
conserved in all of them with a slight variation in the distance between two residues (17
to 25 amino acids, Fig. 4.7.).
SUR1/ABCC8 is a K+ channel regulator involved in modulating insulin secretion
at the plasma membrane. In collaboration with Dr. Joseph Bryan, we isolated a mutant
SUR1/ABCC8 where the conserved cysteine residue is mutated from a patient with
defective K+ channel function, and therefore, with aberrant insulin secretion. To test
whether the Cys mutant SUR1/ABCC8 was also ER retained as seen in ABCB6, we
generated mutant constructs where Cys8 or Cys26 is mutated. The remaining 27 cysteine
residues have been substituted with alanine or serine residues. The mutant SUR1 proteins
were co-expressed with K+ channel, KIR6.2 in Cosm6 cells and were labeled with [125I]azidoglibenclamide. Proteins were fractionated by SDS-PAGE and the mature
glycosylated SUR1 was identified by a lower mobility on the gel. The presence of the
mature glycosylated SUR1 correlated with its surface expression (data not shown). As
reported previously, mature form of SUR1 was observed only when KIR6.2 was coexpressed. Notably, the mature form of SUR1 was absent when one or both of the
conserved cysteine residues were substituted with alanine or serine residues (Fig. 4.7.).
4.4. Discussion
4.4.1. N-Terminal Disulfide Bond Regulates ER Exit of ABC Transporters
The mitochondrial membrane localization of the porphyrin transporter ABCB6
has been shown by three independent studies [171, 204, 250]. Additionally, we, and
others, have shown that ABCB6 specifically localizes to the mitochondrial outer
membrane [204, 250]. Nonetheless, how ABCB6 reaches the mitochondrial outer
membrane is important to understanding its function. An important key was our finding
that ABCB6 is modified by glycan addition. Moreover, ABCB6 utilizes a single unique
glycosylation site that is conserved among mammalian ABCB6, but heretofore only
found in secreted proteins. This unique glycosylation site led to the identification of two
conserved cysteine residues that are found in many ABC transporters and mutation within
one ABCC family member (SUR1/ABCC8) is the genetic basis for the loss of function
due to impaired membrane trafficking.
In this study, we demonstrate that the two cysteine residues in the N-terminus of
ABCB6 and SUR1 are an important ER exit signal. Substitution of cysteine residues in
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Figure 4.7. N-terminal cysteines are conserved in long MRPs and regulate
trafficking.
A) Amino acid sequence alignment of ABCC1, C2, C3, C6, C8, and C9 is shown.
Conserved cysteine residues are boxed in red and glycosylation sites are boxed in green.
B) SUR1/ABCC8 constructs containing mutations at Cys6 and/or Cys26 were coexpressed with KIR6.2 in COSm6 cells. SUR1 was labeled with [125I]azidoglibenclamide, fractionated on SDS-PAGE, and detected by autoradiography.
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either ABCB6 or SUR1 with either serine or alanine at conserved positions leads to ER
retention. This finding suggested one of the two related possibilities: i) the disulfide bond
formation between ABCB6 Cys8 and Cys26 provides a loop that is a signal for ER exit or
ii) a reduced cysteine(s) is a signal for ER retention. We favor the former idea because
while single cysteine mutants are retained, double mutations of Cys8 and Cys26 that have
no cysteine also results in a dramatically impaired ER exit. We confirmed that the Nterminus of ABCB6 forms an intramolecular disulfide bond between Cys8 and Cys26 by
showing that the chimeric ABCB6N1-210-Flag migrated faster under non-reducing
conditions. These results indicate that disulfide bond-dependent folding occurs in the Nterminus. Further support for a specific disulfide loop in ABCB6 being required for ER
exit is the finding that an insertion of a cysteine residue at position 10 does not rescue
trafficking defect of ABCB6-C8S mutant.
The ER exit signal, which ABCB6 employs, appears to be different from that of
the thiol retention mechanism, where exposed thiols are recognized by ER protein(s) as a
retention signal [234]. First, most of the proteins that are regulated by thiol retention form
intermolecular disulfide bonds [234] unlike ABCB6 where an intramolecular bond is
formed. Second, in thiol retention, loss of the cysteine residue involved in the disulfide
bond formation usually results in an increased secretion presumably by a lack of
interaction with ER resident protein(s) that normally results in the ER retention [235,
236]. On the other hand, in ABCB6, lack of a disulfide bond due to mutations of both
cysteine residues involved does not rescue the defective ER exit. The disulfide loop may
act as an ER exit signal via two possibilities: i) chaperone proteins dissociate upon the
“disulfide-bonded loop” formation as a result of loss of a cysteine-independent binding
site or ii) the structural change caused by the disulfide-bonded loop may provide a
binding site for other chaperone proteins. At this point, these two possibilities have not
been verified and are subject for future studies.
Like ABCB6, the N-terminal cysteines required for ER exit are found in ABCC
subfamily members that contain an N-terminus that inserts into the ER and is
glycosylated (long MRPs; ABCC1, C2, C3, C6, C8, and C9) [249]. It is notable that nonfunctional ABCC8/SUR1 from a hyperinsulinemic hypoglycemia patient had a single
point mutation in in this conserved cysteines. This single mutation disrupted the
potassium channel function in a hyperinsulinemic hypoglycemia patient. The mutant
SUR1/ABCC8 is ER retained as shown by a lack of mature glycosylated SUR1/ABCC8.
Thus, the N-terminal cysteines found in ABCC8/SUR1 also serve as an ER exit signal,
most likely by through the formation of a disulfide bond. Further support for the role of
the N-terminus is found in studies where the N-terminus of ABCC1 and ABCC2 localize
to the plasma membrane in the absence of rest of the protein [251, 252] and ABCC1
lacking this region (MSD0) has reduced cell surface expression [252]. These results
further support our findings that the N-terminus, which contains the cysteines, is essential
for trafficking of ABCC family members that insert their N-terminus in the ER.
However, disulfide bond formation may be important in other ABC transporters [233]. In
ABCG2, Cys592 and Cys608 form an intramolecular disulfide bond [253]. It is notable
that the spacing between these cysteines is 16 amino acids, which is close to the
separation conserved in ABCB6 and the ABCC family members. The ABCG2 double
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cysteine mutant, C592/608A, lacked BODIPY-prazocin efflux activity and was expressed
at a very low level on the cell surface. These results lend further support to our findings
that the formation of intramolecular disulfide bond is a critical component of ER exit for
many ABC transporters.
4.4.2. ABCB6 Is Processed in the ER and Golgi
In present study, we show that the mitochondrial protein, ABCB6 contains glycan
modifications, which reveal trafficking from the ER to the Golgi. The presence of
glycoproteins in mitochondria has been previously shown although the trafficking of such
glycoproteins to mitochondria from the ER is not fully understood [254]. Translocation
from the mitochondria to the ER was suggested when hepatitis C virus core protein
showed either ER or mitochondrial localization [255]. The core protein localized to the
ER when highly expressed by the CMV promoter but showed mitochondrial localization
when expressed at much lower levels from a tetracycline-regulated promoter [255].
Interestingly, both the hepatitis C virus core protein and human cytomegarovirus UL37
glycoprotein, another viral protein, localize to the ER prior to the mitochondrial
translocation [256]. However, these studies do not provide insight into how ABCB6
moves from the Golgi to the mitochondria.
The N-glycosylation site in ABCB6 is unique because a cysteine residue (N-X-C)
is substituted instead of a serine or threonine as found in most glycoproteins [240]. The
atypical N-X-C motif has been reported only in five other proteins [241-245]. However,
the functional role of this atypical motif is unknown because these proteins contain
typical glycosylation sites, which might mask the function of the atypical site. We show
that the cysteine residue in ABCB6 is not required for glycosylatin because substitution
with a serine residue in the N-glycosylation motif does not affect ABCB6 glycosylation.
Nontheless, analysis of ABCB6 from different species reveals that the asparagine residue
is not conserved in zebrafish whereas the cysteine residue is. This suggests that genomic
sequence upstream of the codon encoding the conserved cysteine residue acquired an Nglycosylation site in mammals.
Our study suggests ABCB6 topology is different from other half transporters. We
have previously shown that the C-terminus of ABCB6 is localized to the cytoplasm
[204]. The ER luminal localization of the N-terminus of ABCB6 indicates a protein with
an odd number of TM helices which places the N and C-termini on the opposite sides of
the ER membrane. This finding eliminated the proposed ABCB6 topological model with
an even number of TM domains [250]; however, it could not distinguish if ABCB6 had
nine TM helices (predicted by TMHMM) or 11 TMs (predicted by HMMTOP). To
reconcile these two models, we inserted artificial glycosylation sites. The TMHMM
membrane topology reveals the presence of a large cytoplasmic loop 3 (amino acids 206382). Interestingly, the naturally occurring ABCB6 splice variant, termed PRP, lacks 50
amino acid residues within this loop. Since PRP does not bind to hemin-agarose as
assessed by pull-down assays [204], we speculate that this loop may be a heme-binding
domain.
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4.4.3. Physiological Implication of the N-Terminal Disulfide Bond
The ABC transporters play important biological roles and provide the means to
regulate the concentration of toxic xenobiotics and metabolites. To fine tune their arrival
at their destination, both cis and trans mechanisms must be available to the cell. Our
studies show that among many ABC transporters, formation of a disulfide bond between
two conserved cysteines is essential for ER exit. Intramolecular disulfide bonds have
been implicated in the post-trans Golgi network sorting of the secretory proteins,
although the effect of DTT on the sorting of proteins was protein and cell type dependent
[257]. For choromograin B, a secretory protein found in many endocrine cells and
neurons, an N-terminal disulfide bond (Cys16 and Cys37) has been shown to play an
important role in sorting into regulated secretory granules rather than constitutive
secretory granules [257]. Although the disulfide bond we identified in this study
determines the ER to Golgi movement, unlike chromograin B, the use of disulfide bonds
as a sorting signal underscores the importance of proper post-translational modifications
for protein trafficking.
Interestingly, our data suggest that in a condition where the disulfide-bonded loop
does not form, ABCB6 will be ER retained and imply that this occurs for other ABC
transporters. In the oxidized environment of ER lumen, the ratio of oxidized to reduced
glutathione (GSSG and GSH, respectively) is much higher compared to that of the
cytoplasm and the glutathione acts as buffer to maintain the redox state. Several
pathophysiological conditions such as aging are known to accompany changes in the
cellular redox state, mostly to the oxidative state. While oxidative stress has been
reported in diabetes, a reductive shift was observed in the microsomal redox status in rats
with streptozotocin-induced diabetes [258]. Our results suggest that the ditribution
patterns of functional ABC transporters may be altered in conditions where the ER redox
status is shifted.
The K+ channel (KIR) and its regulator, SUR1/ABCC8, require oligomerization to
properly target the cell surface [259]. The newly identified conserved cysteines and
presumably the disulfide-bonded loop in SUR1 adds another layer of checkpoint to
ensure that only properly modified proteins leave the ER. While it is difficult to identify
an universal signal for the sorting and trafficking of all ABC transporters, a small
disulfide-bonded loop appears necessary for ER egress of a group of ABC transporters.
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CHAPTER 5. DISCUSSION
The ABC transporters regulate the transmembrane movement of various
compounds in an ATP-dependent manner [2]. At the plasma membrane, ABC
transporters provide an important barrier to protect cells and tissues from the
accumulation of toxic compounds; however, their ability to exclude different classes of
drugs is the basis for many MDR phenotypes in tumor cells [53]. The physiological roles
of ABC transporters extend beyond the barrier function and their importance in many
biological processes is highlighted by their link to several pathophysiological conditions.
For example, mutations in the ABC genes are the genetic basis for many human disorders
including cystic fibrosis, Dubin-Johnson syndrome, immunedeficiency, and X-linked
sideroblastic anemia and ataxia [2]. Although deficiencies of functional ABC transporters
in the humans and the animal models revealed diverse physiological roles of ABC
transporters, there are still many ABC proteins with unknown physiological functions. A
relatively uncharacterized ABC transporter, ABCB6, is a mitochondrial half transporter
with a possible role in iron homeostasis [171]. These previous findings, coupled with our
findings that ABCB6 is highly expressed in the site of definitive erythropoiesis and its
expression is coordinated with heme biosynthesis, prompted us to determine its role in
heme biosynthesis. Our results that ABCB6 binds to various porphyrins, shows CPIIIstimulated ATPase activity, and mediates ATP-dependent heme uptake into mitochondria
all support our hypothesis that ABCB6 is a porphyrin transporter [204]. Moreover,
ABCB6 is ideally located on the mitochondrial outer membrane to transport an anionic
heme precursor, CPgenIII, into the intermembrane space where the next enzyme in the
pathway resides. Indeed, overexpression of ABCB6 accelerates de novo porphyrin
biosynthesis suggesting that ABCB6 facilitates the process by overcoming the
energetically unfavorable transmembrane movement of porphyrins. By using a heminagarose pull-down assay we developed, we demonstrated that ATP binding to ABCB6 is
sufficient to induce a conformational change, which lowered its affinity for its substrate.
Our results are in agreement with a recently published structural data of nucleotide-bound
bacterial ABC protein. Three other mitochondrial ABC transporters have been shown to
reside in the inner membrane, and thus, ABCB6 is the only one to localize on the outer
membrane reported so far. The mitochondrial outer membrane localization has later been
shown by a different group confirming our results [250]. However, recent studies report
ABCB6 localization on different cellular membranes including the plasma membrane,
Golgi, and vesicles [250, 260, 261]. Therefore, how ABCB6 trafficks intracellularly has
been poorly understood. Our results here demonstrate that ABCB6 contains Endo H
resistant glycans, which indicates ER to Golgi movement prior to the mitochondrial
localization. The characterization of the glycan modification on the atypical N-X-C motif
uncovered conserved cysteine residues that are important for ER exit of ABCB6. These
cysteines are found in several other ABC family members and mutation in the conserved
cysteine residue in ABCC8 results in the lack of its cell surface expression and is the
genetic basis for hyperinsulinemic hypoglycemia in a patient.

85

5.1. ABCB6 Is a Homodimeric Mitochondrial Porphyrin Transporter
Substrates of ABC transporters are generally tested for one or more of the
following characteristics: the binding to the transporters, the ability to stimulate ATPase
activity, and the ATP-dependent uptake by the transporters. Substrate binding and the
uptake assays are typically limited by an availability of radiolabeled compounds. In order
to circumvent the use of radiolabeled hemin, our lab has previously utilized a pull-down
assay using hemin conjugated to agarose to test the interaction between ABCG2 and
heme [75]. ABCB6 binds to hemin-agarose specifically and the interaction can be
disrupted by an addition of various porphyrins. Interestingly, only the compounds with
tetrapyrrole ring were able to displace ABCB6 from hemin-agarose effectively. CPIII, an
oxidized form of heme precursor, CPgenIII, was the most effective porphyrin tested in
displacing ABCB6 from hemin-agarose. The commercially available CPIII is used
throughout this study instead of the physiologically relevant CPgenIII, because CPgenIII
is readily oxidized to CPIII in the atmosphere. Another heme precursor, PPIX and a plant
porphyrin, PhA, also competed for binding of ABCB6 to hemin-agarose to a lesser
extent. A monopyrrole, PBG, did not affect the interaction between ABCB6 and heminagarose even though it is a heme precursor suggesting that ABCB6 recognizes a specific
structure. Moreover, vitamin B12, which has a tetrapyrrole backbone as well as a bulky
side chain, was not effective in displacing ABCB6 from hemin-agarose. These results
show that ABCB6 recognizes anionic compounds with a tetrapyrrole ring, but the binding
pocket cannot accommodate a bulky side chain.
The substrate binding promotes ATP binding and a formation of NBD sandwich
dimer, which results in stimulation of ATP hydrolysis. In order to measure ATPase
activity of mitochondrial ABCB6, a cell line stably expressing non-functional Walker A
mutant ABCB6 was established. The Walker A mutant ABCB6 contained glycine residue
in place of conserved lysine residue the Walker A domain, a mutation that has been
shown to disrupt ATP binding or hydrolysis in other ABC transporters [212, 213, 223].
An increase in the vanadate sensitive ATPase activity was observed in only the
mitochondria prepared from K562 cells expressing wild type ABCB6-V5 but not in the
Walker A mutant-V5. The modest increase may be attributed to the following factors: i)
incomplete inhibition of F1Fo-ATPase in the mitochondria masked the much smaller
ABCB6 ATPase activity and ii) both ATPase and transport acitivity of ABCB6 bearing a
V5 tag was lower compared to the Flag-tagged ABCB6 for unknown reasons. Because
the Walker A mutant cell line was established using the V5-tagged molecule, only the
results from the V5-tagged ABCB6 are presented here. The Walker A mutant binds
hemin as assessed by hemin-agarose pull-down assay, which was a useful feature when
testing the uptake of hemin into mitochondria. Lack of ATP-dependent uptake of
radiolabeled hemin into the Walker A mutant expressing mitochondria demonstrated that
the assay measures the actual transport rather than hemin simply binding to the ABCB6
at the membrane. Taken together, hemin meets all the criteria to be a substrate for
ABCB6 and our results imply that other porphyrin are likely to be substrates as well.
ABCB6 is a half transporter with one MSD and one NBD; therefore, it must
homo- or heterodimerize in order to reconstitute transport function. We hypothesized that
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ABCB6 is likely to form a homodimer because there is no potential dimerizing partner on
the mitochondrial outer membrane. Co-imunoprecipitation experiments using differentlytagged ABCB6 show that it homodimerizes. The findings that the overexpression of
ABCB6 alone was sufficient to observe transport activity, etc., also support the
homodimerization of ABCB6. Recently, ABC transporters have been shown to contain
multiple substrate binding sites/pockets that can accommodate structurally different
compounds possibly at the same time [107, 115, 226]. A homodimeric half transporter
ABCG2 has been proposed to contain multiple substrate binding pockets [54]. By
creating a dimerization-deficient ABCB6, we wanted to test whether porphyrin binding
was retained in a single molecule. This would provide some insights into how substrate
binding sites are constituted in ABCB6. However, despite the generation of multiple
mutants, we were unable to identify domain(s) that are important for dimerization, which
may be an indication that the dimer is stabilized through multiple interaction sites.
5.2. ABCB6 Accelerates Porphyrin Biosynthesis
Overexpression of ABCB6 increases a steady state PPIX levels in K562 cells.
This effect was dependent on function of ABCB6 because K562 cells with the Walker A
mutant ABCB6 showed no change in cellular PPIX levels compared to vector cells. We
further demonstrated that de novo porphyrin biosynthesis was upregulated in cells
expressing functional ABCB6. Heme biosynthesis takes place in two compartments
requiring transmembrane movement of intermediates: ALA into the cytosol from
mitochondria and CPgenIII into the mitochondrial intermembrane from the cytosol. The
upregulation of porphyrin biosynthesis by ABCB6 and its function as the mitochondrial
outer membrane transporter pumping porphyrins into the intermembrane space from the
cystosol suggest that ABCB6 plays an important role in heme biosynthesis. Based on
these results, we propose that ABCB6 is the elusive CPgenIII transporter in heme
biosynthesis pathway, which had been an unanswered question in the field for a long
time. CPgenIII readily associates with the membrane via its hydrophobic cyclic rings;
however, the anionic side chains do not allow the transmembrane movement to occur
easily. Indeed, previous studies show that the rate of simple diffusion of CPgenIII is not
sufficient to support robust heme biosynthesis in differentiating erythroid cells and the
presence of energy-dependent transport has been suggested [192, 193]. The movement of
CPgenIII may represent yet another rate-limiting step in heme biosynthesis that ABCB6
can overcome.
5.3. ATP Binding Releases the Substrate from ABCB6
The transmembrane movement of compounds by ABC transporters is ATPdependent. Initial biochemical studies led to a model that ATP hydrolysis provided the
power stroke for the transport [113]. However, structural data of isolated NBDs and
recent biochemical studies suggest that formation of a NBD dimer induced by substrate
and/or ATP binding is the power stroke for the substrate transport [97, 114]. This change
in the conformation of NBD is then transmitted to MSD, which causes a sufficient
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conformational change to release substrates on the other side of the membrane. Our
results support the latter model, referred to as “ATP switch model,” in which binding of
ATP induces a conformational change to a low affinity state for the substrate of ABCB6.
Taking advantage of the affinity of ABCB6 for hemin-agarose, we demonstrated that
addition of ATP at room temperature was sufficient to release ABCB6 from heminagarose. Furthermore, non-hydrolyzable ATP anolog, AMPPNP, had a similar effect on
the release of ABCB6 from hemin-agarose, although a higher concentration was required.
Effects of mutating the conserved lysine residue in the Walker A domain varies among
the ABC transporters. Walker A mutation in some ABC transporters results in a loss of
ATP binding and subsequently ATP hydrolysis, whereas only the ATP hydrolysis is
disrupted in others [213]. For ABCB6, loss of the conserved lysine residue resulted in a
severely impaired ATP binding. Therefore, as expected, the Walker A mutant ABCB6
remained bound to hemin-agarose after ATP or AMPPNP addition.
Although structural data for mammalian ABC transporters are not available at this
time, the structure of bacterial ABC transporter Sav1866 provided insights into the
possible transport mechanism that is likely to be similar in the mammalian counterpart.
The cytoplasmic loop from one subunit reaches over to contact the NBD from the other
subunit and this interface may be important in transmitting information from NBDs to
MSDs and vice versa [97]. The MSDs of nucleotide bound Sav1866 is forming outward
wings, which suggests that it is in a position to release its substrate [97]. It has been
shown that ATP hydrolysis and subsequent release of Pi and ADP disengages the NBD
dimer suggesting that this process is involved in resetting the transporter to a high affinity
state for the next transport cycle [114]. Our results show that ATP binding induces a
sufficient conformational change and supports the transport mode described as the ATP
switch model. However, understanding the precise mechanism requires further
investigation. For some full transporters and heterodimeric half transporters, two NBDs
are shown to be asymmetrical. The binding and hydrolysis of ATP require two NBDs
because a functional ATPase site comprises of domains from the both NBDs [110]. For
TAP1/TAP2 heterodimer, only one ATPase site contains consensus Walker B, histidine
switch, and ABC signature motifs [111]. The consensus ATPase site is considered to
provide the power stroke for peptide translocation by TAP1/TAP2. The combination of
one consensus and one degenerate ATPase sites is seen in more than 20 ABC transporters
[111], and therefore, the asymmetrical NBDs may reveal an important aspect of substrate
transport. Whether a homodimer such as ABCB6 contains an asymmetry in its NBD
dimer remains to be seen.
5.4. ABCB6 Is Glycosylated and Contains a Disulfide-Bonded Loop That Acts as a
Trafficking Signal
The initial identification of ABCB6 showed that it localized on the mitochondria
[171]. Subsequently, we, and others showed its localization on the mitochondrial outer
membrane [204, 250]. However, recent studies showed the localization of ABCB6 on
other subcellular membranes such as the plasma membrane and the Golgi [250, 261].
Therefore, understanding ABCB6 intracellular trafficking may provide insights into how

88

ABCB6 reaches the mitochondrial outer membrane and other membranes. The objective
was to study how ABCB6 trafficks in cells, as well as to identify if any signals for sorting
or trafficking exist within ABCB6. The unexpected observation that ABCB6 is modified
with Endo H resistant glycans, mitochondrial proteins are usually not glycosylated,
indicated that ABCB6 trafficks to mitochondria via an unconventional way. Furthermore,
the glycosylation site of ABCB6 consists of N-X-C instead of a typical N-X-S/T site. By
characterizing the atypical glycosylation site, we demonstrate that the conserved cysteine
residue, along with another cysteine residue in the N-terminus, plays an important role in
ER exit of ABCB6. Interestingly, these cysteines are conserved in ABCC subfamily
members that extrude the N-terminus into the ER lumen during maturation (long MRPs).
This motif was functional in at least one of the long MRPs. Loss of the conserved
cysteine in SUR1/ABCC8 results in a lack of cell surface expression and the lack of
functional SUR1/ABCC8 is the genetic basis for a case of hyperinsulinemic
hypoglycemia.
5.4.1. Formation of Disulfide Bond in ABCB6 Acts as an ER Exit Signal
Post-translational modifications such as signal sequence cleavage, Nglycosylation, and disulfide bond formation occur and are monitored in the ER to ensure
that only properly modified proteins leave the ER. We found that when the cysteine
residue (Cys8) in the glycosylation site of ABCB6 is substituted with serine, ABCB6 is
still modified but with Endo H sensitive glycans. Glycans are Endo H sensitive when
they are attached to proteins in the ER but acquire Endo H resistance after processing in
Golgi. Therefore, Endo H sensitive glycans on C8S mutant indicated that it failed to exit
the ER. The only other cysteine residue predicted to be exposed to the ER lumen is
Cys26 and it is highly conserved among other species. The mutant ABCB6 where Cys26
is substituted with serine or alanine also contained Endo H sensitive glycans. We also
confirmed that these two conserved cysteine residues, Cys8 and Cys26, form an
intramolecular disulfide bond that appears to be glycan-independent. Oxidative state of
cysteine residues has been shown to regulate secretion of several proteins including IgM
through a mechanism called “thiol retention” [234]. The cysteine residues monitored in
thiol retention needs to oxidize through disulfide bond or by other means to exit the ER.
ABCB6 does not appear to be regulated by thiol retention because mutation of both Cys8
and Cys26 did not rescue the defective ER exit. Taken together, we propose that the
disulfide-bonded loop at the N-terminus is a novel ER exit signal.
How the disulfide-bonded loop acts as an ER exit signal is yet to be determined.
However, there are two possibilities: i) chaperones dissociate upon the formation of the
loop as a result of loss of a binding site or ii) the loop formation creates a binding site for
other chaperone proteins. It will be interesting to determine if there is a stable interaction
between C8S or C26A mutant and ER resident proteins.
Many ABC transporters contain even number of TM helices and therefore have
both N- and C-termini in the cytosol. However, there is a subset of ABC transporters in
ABCC subfamily, which contain an additional five TM helices N-terminal to the
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MSD1.The glycan modifications on the N-termini of these “long MRPs” indicate that
their N-termini extrude into the ER lumen. The conserved cysteines identified in ABCB6
are conserved in the long MRPs, ABCC1, C2, C3, C6, C8, and C9. The functionality of
these cysteines are conserved at least in one of them, ABCC8/SUR1. Loss of one or both
of the conserved cysteine residues results in the defective trafficking of SUR1/ABCC8.
The mutation in the conserved cysteine residue in SUR1/ABCC8 was isolated from a
patient with hyperinsulinemic hypoglycemia indicating that the failure to exit the ER is
the cause of the disease. We have also observed some functional consequences to the loss
of the conserved cysteine residues in ABCB6. Our preliminary results show that the
unlike wild type ABCB6 expressing K562 cells, cells expressing C8S or C26A mutants
have steady state PPIX levels that are comparable to the Walker A mutant cells.
5.4.2. Intracellular Movement of ABCB6
The glycan modification on ABCB6 was unexpected because normally,
mitochondrial proteins reach their destination after being fully translated in the cytosol.
There is evidence for proteins moving from the ER to mitochondria. However, how
proteins traffick from Golgi to mitochondria is poorly understood. Further investigation is
required to identify how ABCB6 properly targets mitochondria.
The glycosylation at the very N-terminus revealed a unique topology of ABCB6.
Half transporters typically contain six TM helices, thus positioning both N- and C-termini
in the cytosol. Because the N-terminus of ABCB6 is in the ER lumen but its C-terminus
is in the cytosol, ABCB6 is predicted to contain an odd number of TM helices. Also, the
regions that contain consensus N-X-S/T sites are likely to reside in the cytosol due to the
lack of glycosylation. Based on these criteria and the results from the glycosylation site
insertion experiment, we favor the membrane topology model predicted by TMHMM,
which has nine TM helices. Half transporters in ABCB subfamily, TAP1 and TAP2, have
been shown to contain 10 and nine TM helices, respectively. These N-terminal extensions
are important for interaction with tapasin. Perhaps, the additional three TM helices in
ABCB6 play an important role in regulating its function or act as a binding site for other
proteins.
5.5. Conclusion
We have characterized the substrate, physiological role, transport mechanism, and
trafficking signal of ABCB6. Since many ABC transporters are able to recognize
structurally different compounds, many more substrates for ABCB6 may be identified in
the future. It will be exciting to see if ABCB6 is involved in other biological processes.
Moreover, tumor cells exhibit a high rate of heme biosynthesis, which is the basis for
photodynamic therapy [190]. Therefore, whether ABCB6 is upregulated in these cells to
facilitate heme biosynthesis will be of interest. The identification of the N-terminal
disulfide-bonded loop formed by conserved cysteines has a broad implication for other
ABC transporters as the motif is found in ABCC subfamily members. ABCC1 is one of
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the three major drug transporters, and ABCC2, ABCC6, SUR1/ABCC8 and
SUR2/ABCC9 are linked to human disorders (Dubin Johnson syndrome, PXE, FPHHI,
and DCVT, respectively). Therefore, mutations in the conserved cysteine residues may
result in a lack of cell surface expression of these transporters and, therefore, may lead to
the above mentioned disorders. Furthermore, our results suggest that the cell surface
expression pattern of these transporters may be altered in pathophysiological conditions
that affect ER redox status.
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